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The purpose of the study was to validate an existing clinical risk 
assessment tool (Ammann tool) to predict adverse events (AEs) in 
children with cancer and febrile neutropenia (FN).  
 
Patients and methods 
Patients less than 16 years of age with confirmed malignancies receiving 
chemotherapy and who presented to the Tygerberg hospital paediatric 
oncology unit, with fever (axillary temperature > 38 C twice in 24 hours 
or > 38.5 C once) and neutropenia (neutrophil count < 500 cells/mm3) 
were enrolled. A risk prediction score1 was calculated for each patient 
according to the Ammann rule, and AEs were documented until 
antibiotics had been stopped and neutropenia resolved. The risk 
prediction score included haemoglobin > 9 g/dL, white cell count < 0.3 
g/L, platelet count < 50 g/L and chemotherapy more intensive than acute 
lymphoblastic leukaemia maintenance therapy. AEs were defined as 
severe medical complications, microbiologically defined infection and 
radiologically confirmed pneumonia. 
 
Results 
There were 100 FN episodes in 52 patients, of whom 54% had 
haematological malignancies, 44% solid tumours and 2% central 
nervous system tumours (relapsed malignancies 16%). The male:female 
ratio was 1.8:1 with a median age of 56 months (mean age of 71 months; 
range 8 to 175 months). AEs occurred in 18/57 (45%) patients with a 
low risk (score < 9) and 22/43 (55%) with a high risk (score ≥ 9), yielding 
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a sensitivity of 56.8%, specificity of 65%, positive predictive value of 
50% and negative predictive value of 71%. Total WCC (p = < 0.01) and 
absolute monocyte count (p = 0.05) were significantly associated with 
an AE. Antibiotic-resistant microorganisms were found in 18% of 
microbiologically confirmed FN. There were marked differences in the 
patient cohorts between high-income countries versus a low- to middle-
income country with a lower median age and more resistant organisms. 
 
Conclusion 
Although this study did not succeed in validating the risk assessment tool 
(Ammann tool), it demonstrated the important association between total 
WCC, absolute monocyte count and an AE during FN.  
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Opsomming         
Doel 
Die doel van die studie was om ’n bestaande instrument vir kliniese 
risikobepaling (die Ammann-instrument) vir die voorspelling van 
ongewenste gebeure by kinders met kanker en koorsige neutropenie te 
staaf.  
 
Pasiënte en metodes 
Pasiënte jonger as 16 jaar wat chemoterapie vir bevestigde 
kwaadaardighede ontvang en wat koors (okseltemperatuur >38 C twee 
keer binne 24 uur, of >38,5 C eenmalig) sowel as neutropenie het 
(neutrofieltelling <500 selle/mm3), is in die studie opgeneem. ’n 
Risikovoorspellingstelling1 is volgens die Ammann-reël vir elke pasiënt 
bereken en ongewenste gebeure is aangeteken totdat antibiotika gestaak 
is en neutropenie opgeklaar het. Die risikovoorspellingstelling het 
ingesluit hemoglobien >9 g/dL, ’n witseltelling <0,3 g/L, ’n 
plaatjietelling <50 g/L, en meer intensiewe chemoterapie as 
instandhoudingsbehandeling vir akute limfoblastiese leukemie. 
Ongewenste gebeure is omskryf as ernstige mediese komplikasies, 




Daar was 100 episodes van koorsige neutropenie by 52 pasiënte, van wie 
54% hematologiese kwaadaardighede, 44% soliede tumore en 2% 
tumore in die sentrale senustelsel gehad het (terugkerende 
kwaadaardigheid 16%). Die verhouding manlike tot vroulike pasiënte 
was 1,8:1 en die mediaanouderdom 56 maande (gemiddelde ouderdom 
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71 maande; ouderdomsbestek 8 tot 175 maande). Ongewenste gebeure 
het by 18 van die 57 pasiënte (45%) met ’n lae risiko (telling <9) en by 
22 van die 43 pasiënte (55%) met ’n hoë risiko (telling >9) voorgekom, 
wat ’n sensitiwiteitswaarde van 56.8%, ’n spesifisiteitswaarde van 65%, 
’n positiewe voorspellingswaarde van 50% en ’n negatiewe 
voorspellingswaarde van 70.9% opgelewer het. Die totale witseltelling 
(p = <0,01) en absolute monosiettelling (p = 0,05) het ’n beduidende 
verband met ongewenste gebeure getoon. Antibiotikumweerstandige 
mikro-organismes is in 18% van die mikrobiologies bevestigde gevalle 
van koorsige neutropenie aangetref. 
Gevolgtrekking 
Hoewel hierdie studie nie die risikobepalingsinstrument (Ammann-
instrument) kon staaf nie, het dit die belangrike verwantskap tussen die 
totale witseltelling, absolute monosiettelling en ongewenste gebeure 
gedurende koorsige neutropenie aan die lig gebring. Daar was duidelike 
verskille in die pasiëntkohorte van hoëinkomstelande en dié van ’n lae- 
tot middelinkomsteland met ’n laer mediaanouderdom en meer 
weerstandige organismes. 
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CHAPTER 1: INTRODUCTION        
 
1.1 Background and context 
 
Childhood cancer represents 1-10% of all cancers,1 with an annual incidence of 70-160 per 
million globally2 and 45 per million in South Africa.3 It remains the second most common 
cause of death in both the United States of America (USA)4 and the United Kingdom (UK),5 
contributing up to 8% of the postneonatal mortality rate worldwide.6 
  
Despite improvements in overall survival due to improved supportive care, febrile neutropenia 
(FN) remains one of the most common complications of chemotherapy.7,8 
 
There is no current evidence-based method to accurately rule out an infectious cause of fever; 
therefore, FN episodes are managed according to the standard approach of hospital admission 
and intravenous antibiotics.9,10 Recent guidelines recommend the use of a validated scoring 
system to assess the risk of infectious complications and individualised patient management.9 
 
A risk prediction strategy will assist in differentiating patients at high risk of bacteraemia, 
invasive bacterial infection (IBI) and/or death from low-risk patients in whom the possibility 
of early step-down to oral antibiotics and outpatient treatment can be considered.11 
 
This prospective study aimed to validate a risk assessment tool published by Ammann et al12 
to distinguish between high-risk and low-risk paediatric oncology patients who might develop 
adverse events (AEs) during FN at the Tygerberg Paediatric oncology unit. Identification of a 
low-risk group would enable early step-down from intravenous to oral antibiotics that could 
benefit the institution financially, with a reduction in discomfort to the patients. A risk 
stratification would also assist with early recognition of complications through intensive 
monitoring of high-risk patients.  
 
1.2  Literature review 
  
Childhood cancer represents 1-10% of all cancers globally, with approximately 160 000 new 
cases diagnosed annually, resulting in approximately 90 000 deaths per annum.1 According to 
the International Incidence of Childhood Cancer (Vol. 2), the global age-standardised annual 
incidence has been estimated to be between 70 and 160 per million in children aged 0 -14 
years.2 In South Africa, the incidence of childhood cancer has been estimated to be 
approximately 45 per million.3 Despite its low incidence, childhood cancer remains the second 
most common cause of death in children aged 5-14 years in both the USA4 and the UK,5 
contributing up to 8% of the global postneonatal mortality rate, according to a report by the 
World Health Organization (WHO) in 2015.6  
  
The five-year overall survival for childhood cancer has been estimated to be as high as 75%, 
but despite huge improvements in supportive care, close to 16% of deaths within five years of 
diagnosis are the result of treatment complications.7,8 A South African study reported the 
overall survival rate in two South African units to be 52.1%,13 much lower than the up to 80% 
five-year survival rate in the USA14 and the UK.15 This lower survival rate was attributed to the 
lower survival of black and mixed-race (coloured) children, probably due to poor nutritional 
status, advanced disease at diagnosis, genetic factors and associated comorbidities (e.g. human 
immunodeficiency virus [HIV] infection and tuberculosis [TB]).13   
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A study from the UK found that despite a reduction in treatment related-deaths in children with 
acute lymphoblastic leukaemia (ALL), infections remained the main cause of death.16 The 
majority (85%) of febrile episodes had a bacterial origin, but they could also be the result of 
viral or fungal infections, blood product transfusions, drug reactions or the malignancy itself.8 
  
Castagnola et al reported that neutropenia complicated by fever occurred in 34% of their study 
population in a prospective study.17 The incidence and rate of febrile complications varied 
according to the treatment phase, occurring in more than 40% of neutropenia episodes 
associated with intensive treatment for acute leukaemia or non-Hodgkin lymphoma, or in 
preparation for haematopoietic stem cell transplantation. Fever of unknown origin was the most 
common clinical diagnosis (79% of cases), with bacteraemia demonstrated in only 10% of 
cases.17  
  
There is no current evidence-based method to accurately rule out an infectious cause of fever; 
therefore, FN episodes are managed according to the standard approach of hospital admission 
and intravenous antibiotics.9,10  
A risk prediction strategy will assist in differentiating patients at high risk of bacteraemia, IBI 
and/or death from low-risk patients in whom the possibility of early step-down to oral 
antibiotics and outpatient treatment can be considered.11  
 
High-risk patients will need a more aggressive treatment approach with intensive monitoring, 
broad-spectrum intravenous antibiotics and hospitalisation until resolution of fever, 
neutropenia and signs of infection, in other words, the current standard approach.9,10,11 For the 
low-risk group, however, a less aggressive approach could result in a shortened antimicrobial 
course, reduced length of hospitalisation and improvement of the patients’ quality of life with 
reduced cost to the institution.8,11 
  
The Multinational Association for Supportive Care in Cancer18 describes a clinical risk index 
that identifies adult patients with FN at low risk for complications with a positive predictive 
value (PPV) of 91%, a specificity of 68% and a sensitivity of 71%. The score includes factors 
such as a systolic blood pressure of more than 90 mmHg, active chronic obstructive pulmonary 
disease (COPD), solid tumour as type, previous fungal infection in a patient with 
a haematological malignancy, dehydration requiring intravenous fluids, clinical setting at onset 
of fever and age less than 60 years. As the Multinational Association for Supportive Care in 
Cancer rule does not include children and due to the rare complication of COPD in children, 
this rule is of very limited applicability in the paediatric age group.18 
 
A 2010 systematic review and meta-analysis of the performance of risk prediction rules in 
children and young people with FN assessed 20 studies and 16 different clinical decision rules 
in 8 388 episodes of FN and concluded that no system was more effective or reliable than any 
other.8 In a 2012 update, despite nine further risk prediction models evaluated, no rule was 
identified as superior.19 As part of its findings, this study concluded that undertaking risk 
stratification 24-48 hours after the onset of the episode led to much better discrimination as 
many occult infections would have become clinically apparent during this period.19 
  
In one of the first attempts to identify a clinical decision rule, Rackoff, Gonin, Robinson, 
Kreissman & Breitfield found that there was an increased risk of bacteraemia with a fever 
higher than 39 °C and an absolute monocyte count (AMC) of less than 0.1 × 109/L at the time 
of presentation.20  
This was the only rule that could be assessed over several datasets in the 2010 systematic 
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review but was found to lack discriminatory ability.8 A similar retrospective study, focusing 
on clinical decision rules predicting bacteraemia and the need for intensive care unit (ICU) 
admission from 1990 to 1996, found a bacteraemia rate of 14% and only 11 (0.9%) out of 1 171 
FN episodes resulting in ICU admissions.21 The lowest frequency of bacteraemia (6.1%) 
occurred in children with an AMC of more than or equal to 0.155 x 109/L (sensitivity of 94%; 
specificity of 17%) on admission. None of the patients identified as low risk according to AMC 
required ICU admission or died. Level of absolute neutrophil count (ANC), absolute phagocyte 
count (APC), temperature or platelet count could not be associated with a statistically 
significant decrease in the risk for bacteraemia. Applying the rule of an AMC of more than or 
equal to 0.1 × 109/L (Rackoff et al20), the researchers demonstrated a bacteraemia rate of 8.7%, 
significantly higher than the rate of 6.1% for an AMC more than or equal to 0.155  109/L.21 
 
Alexander, Kelly, Hibberd & Parsons (1995) classified patients as low risk if they were 
outpatients at the time of presentation, had an anticipated duration of neutropenia of less than 
seven days and had no significant comorbidity.22 The researchers compared the incidence of 
AEs in the high- and low-risk groups, determining a rate of 4% in the low-risk group versus 
41% in the high-risk group.22 Klaassen, Goodman, Pham & Doyle (2000) performed a 
prospective study (1996-1998) that derived and validated a ‘low-risk’ prediction rule.23 During 
227 episodes of FN in 140 patients, 13 prediction variables were prospectively collected in 
98% of the episodes but only 1 rule could be validated. It was found that patients whose AMC 
was more than 0.1 × 109/L at the time of presentation had an 8% and a 5% incidence of 
significant bacterial infection and bacteraemia respectively, versus 25% and 17% in the high-
risk group (monocyte count less than 0.1 × 109/L).23 This correlates with the low incidence of 
bacteraemia found by Baorto, Aquino, Mullen, Buchanan & Debaun21 and validated the 
Rackoff rule.20 In the 136 episodes of FN included in the validation set, the incidence of 
significant bacterial infection/bacteraemia was 12/5% if the patient was low risk (monocyte 
count > 0.1 × 109/L) versus 25/22% if the patient was high risk (monocyte count < 0.1 × 109/L). 
This translated into a 74% sensitivity in predicting a low-risk group, a 46% specificity and a 
negative predictive value (NPV) of 88%.23 The researchers could not validate a temperature 
higher than 39 °C as an independent risk factor.23  
 
Santolaya et al, in a prospective multicentre study, identified five factors (C-reactive protein 
[CRP] more than or equal to 90 mg/L, presence of hypotension, presence of leukaemia, platelet 
count less than or equal to 50 000/mm3 and recent chemotherapy) to be associated with an 
increased risk of IBI.24 The researchers’ predictive model demonstrated an increasing risk of 
IBI according to the number of risk factors present at the time of enrolment, and absence of 
these risk factors was associated with IBI in only 2%. Elevated CRP as the sole variable had a 
38% risk of IBI compared with 17% for low platelets and 21% for recent chemotherapy. 
Children with two or more risk factors had a risk of IBI that surpassed 48%. High fever and 
low monocyte count did not reach significance in the researchers’ multivariate analysis.24 
 
Santolaya et al (1999 to 2000) performed a prospective evaluation of the above five factors, 
demonstrating a sensitivity of 92%, a specificity of 76%, a PPV of 82% and an NPV of 90%.25 
Phillips, Lehrnbecher, Alexander & Sung (2012) et el, however, concluded in their meta-
analysis that the rule had been developed and tested in Chile, which might limit its applicability 
in Europe and North America.19 In a similar study, Asturias et al could establish no statistical 
relationship between the above five risk factors, malnutrition and bacteraemia.26 Asturias, 
Corral & Quezada (2010) did, however, find that increasing CRP values were directly related 
to the number of days with fever during hospitalisation and with mortality due to 
infection. Thrombocytopenia also seemed to be related to an increase in the number of days 
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with fever and prolonged hospitalisation.26 
  
In a multivariate analysis Rondinelli, Ribeiri & de Camargo (2006)27 determined variables that 
remained as independent predictive risk factors for severe infectious complications (SICs), 
which include age less than five years, use of a central venous catheter (CVC), temperature 
more than 38.5 °C, Hb level less than 7 g/dL (in contrast to the Swiss Paediatric Oncology 
Group [SPOG] 2003 findings), any clinical focus of infection on first examination and absence 
of upper respiratory tract infection (URTI) as a model for scoring SICs.27 Two validation 
datasets of the Rondinelli rule demonstrated a sensitivity of 84% and 62%.19 
  
Paganini et al studied a weighted score, predicting mortality based on the presence of advanced-
stage underlying malignant disease, presence of associated comorbidity and presence of 
bacteraemia.28 The scoring system according to mortality-related risk factors reached a 
sensitivity of 100% and a specificity of 84.2% during the derivation set, and a sensitivity of 
84.2%, a specificity of 83.2% and an NPV of 99.54% for predicting mortality in the validation 
set.28 
 
Ammann, Hirt, Lüthy & Aebi derived a scoring system predicting severe bacterial infection 
based on seven variables with a 96% sensitivity, a 26% cross-validated specificity and an NPV 
of 91% in a retrospective, single-site cohort study over an eight-year period (1993-2001).29 The 
7 variables were identified from a total of 39 covariates with possible relevance to severe 
bacterial infection and that were accessible to the treating physicians within the first 2 hours 
after fulfilment of the criteria for FN. Weighted factors included bone marrow involvement, no 
clinical signs of viral infection, high serum CRP levels, leukopenia, presence of a CVC, high 
Hb levels and a diagnosis of pre-B-cell ALL.29 During the systematic review by Phillips et al, 
three studies provided data to test this rule with a pooled average sensitivity of 98% but a 
pooled average specificity of only 13%.19 The SPOG 2003 trials developed a weighted scoring 
system for the prediction of bacteraemia at reassessment and identified 4 variables in a subset 
of 423 FN episodes, which included a Hb level more than or equal to 9 g/dL (weight 3), a 
platelet count less than 50 g/L (weight 3), shaking chills (weight 5) and another reason for 
inpatient treatment or observation (weight 3).30 Applying a threshold of more than or equal to 
three, the score, which was simplified into a low-risk checklist, predicted bacteraemia with 
100% sensitivity and 15% specificity. The researchers concluded that predicting bacteraemia 
at reassessment (at 8-24 hours) was better than the prediction at presentation.30 In assessing 
factors that would predict future AEs in a different subset of patients included in the SPOG 
2003 study population, Ammann et al developed a weighted score with four variables through 
a multivariate mixed logistic regression model.1 Using preceding chemotherapy that is more 
intensive than ALL maintenance treatment (weight = 4), Hb level more than or equal to 9 g/dL 
(weight = 5), leukocyte count less than 0.3 g/L (weight = 3) and platelet count less than 50 g/L 
(weight = 3), a score (sum of weights) more than or equal to nine predicted future AEs with an 
overall sensitivity of 92%, a specificity of 45% and an NPV of 93%. The score’s predictive 
value and sensitivity increased when used at reassessment at 8-24 hours. Of concern, however, 
was that only one of the three patients who died during the study would have been identified 
as being at high risk of an AE according to this prediction score.12 
 
 
Miedema et al attempted to validate the Ammann prediction rule12 in their study population in 
the Netherlands and demonstrated a sensitivity of only 69% at first presentation and 82% upon 
reassessment at 8-24 hours.31 Applying this prediction rule to their study population, one in 
three patients with bacteraemia was incorrectly classified as being at low risk of AEs. The 
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researchers attributed these differences in sensitivity to differences in treatment protocols, 
microbiological environment, retrospective data collection and genetic factors.31 
 
Severe medical complications (SMCs), defined as potentially life-threatening complications, 
the need for transfer to the paediatric ICU or death, were assessed in another subset of the 
SPOG 2003 FN study, and it was found that an SMC was reported in 5.6% of 443 FN episodes, 
identifying 4 characteristics significantly and independently associated, namely diagnosis of 
acute myeloblastic leukaemia (AML), 7 days or less since last chemotherapy, severely reduced 
general condition and HB level less than or equal to 90 g/L.32 The group concluded that SMCs 
were rare in children with FN and mortality was very low. Those with an SMC often had a 
delayed onset and biphasic clinical course with secondary deterioration.32 In a more recent 
study from Iran, five variables were identified that, if all present, were associated with a 100% 
risk of a life-threatening infection.33 These variables were temperature more than or equal to 
39 °C, presence of mucositis, abnormal chest radiograph, platelet count less than 20 000 
cells/mm3 and neutrophil count less than 100 cells/mm3.33 
 
Many studies on the appropriate treatment of FN have been conducted. A Canadian survey 
(2005) found several modified treatment regimens, varying from traditional inpatient 
management with antibiotics until neutropenia resolved to alternative regimens in which 
antibiotics were only continued until the patient was afebrile for 5-7 days.34 In 1 of the subsets 
of the prospective multicentre SPOG 2003 FN study, patients were found to be low risk 
according to 10 predefined low-risk criteria, and 6 additional criteria were randomised into an 
experimental group (stepped down to oral antibiotics within 24 hours) and a control group. The 
experimental treatment was not shown to be noninferior to the standard treatment (100% vs. 
97%), but a limitation was the premature closure because of insufficient patient accrual, 
resulting in a very small power to detect noninferiority regarding safety.11  
  
Ammann (2004) reviewed available data to support outpatient oral antibiotic use in low-risk 
episodes of FN and found three single-centre randomised controlled trials comparing oral to 
intravenous antimicrobial therapy.35 The researchers concluded that although these studies had 
found no significant differences in mortality and treatment success, they were all underpowered 
and due to their exclusion criteria could not be applied to the average patient cohort in most 
paediatric oncology units.35 
   
Several studies assessing biomarkers for their predictive value in FN have been performed. 
Secmeer et al compared the diagnostic and follow-up value of procalcitonin (PCT) compared 
to CRP and erythrocyte sedimentation rate (ESR) in documenting infection in patients with FN 
undergoing intensive chemotherapy and found PCT and CRP levels to be significantly higher 
in FN patients than in the control group (cancer patients without fever).36 ESR showed no 
significant difference. In sequential analyses of patients without documented infections, the 
median of PCT concentrations showed a tendency to decrease after 8 hours after the onset of 
fever, whereas in patients with documented infection, it only decreased after 48 hours. The 
researchers also found that the PCT concentrations remained the same over the entire period in 
patients with prolonged fever (more than 72 hours).  
They concluded that PCT was a more sensitive marker for early detection of bacterial infection, 
especially taking into consideration the slow rise in CRP levels.36 Miedema et al concluded that 
interleukin (IL)-8 was the most useful marker for the early detection of bacterial infections but 
because it is influenced by the presence of gastrointestinal mucositis (in contrast to PCT levels 
that are not affected), PCT might be more useful.37 IL-8 used in combination with clinical 
parameters or PCT reached 100% sensitivity in identifying bacterial infection. With sequential 
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testing after 24-48 hours, only PCT remained elevated in bacterial infections, while IL-8 
remained significantly increased during mucositis.37 Kitanovski, Jazbec, Hojker, Gubina & 
Dergane (2006) reported that IL-6 and PCT were more sensitive and specific as early markers 
of bacteraemia/clinical sepsis than CRP in children with FN and that sequential PCT 
determinations improved its diagnostic accuracy.38 Mian et al divided patients with FN into a 
high-risk and a low-risk group according to predefined criteria (prolonged hospitalisation for 
7 or more days, admission to a paediatric ICU or a confirmed bacteraemia) to analyse the 18 
serum biomarkers, including CRP, PCT and ILs.39 Upon presentation, a PCT level > 0.11 
mg/ml had a 97% sensitivity to predict high risk for FN, while a CRP level of > 100 mg/L had 
a sensitivity of 88%.39 
  
Based on the literature presented above, it becomes apparent that although many researchers 
have undertaken the task of identifying an accurate prediction rule, few rules have been 
successfully validated. Identification of a low-risk group would enable early step-down from 
intravenous to oral antibiotics that would financially benefit the institution, with a reduction in 
discomfort to the patients. A risk stratification would also assist with early recognition of 
complications through intensive monitoring of high-risk patients. As already mentioned, 
Ammann developed a risk prediction model during the SPOG 2003 trials.12 Using basic 
information on chemotherapy and blood tests available shortly after admission, they predicted 
AEs with a 92% sensitivity. Using the same outcomes and definitions in my study, we aimed 
to validate the sensitivity, specificity, PPV and NPV of the Ammann rule in our patient 
population. 
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CHAPTER 2: RESEARCH DESIGN AND METHODOLOGY    
 
2.1 Purpose of the study 
 
The purpose of the study was to validate an existing clinical risk assessment tool (Ammann 
tool12) to predict AEs in children with cancer and FN, using four variables, including Hb level, 
total WCC, platelet count and phase of chemotherapy, to distinguish between high-risk and 




2.2.1 Primary objective 
The primary objective was to validate the sensitivity, specificity, PPV and NPV of the clinical 
risk assessment tool (Ammann tool1) in our study population. 
 
2.2.2 Secondary objectives 
 Identification of risk factors that could predict a group of patients at high risk of an 
AE during FN.  
 Identification of factors predicting a low-risk patient group with no AEs during FN.  
 Identification of additional factors associated with an AE.  
 Identification of the current micro-organism profile and sensitivities with 
subsequent review of the current antibiotic protocol use.  
 Cross-validation of other predefined risk prediction tools including the rules derived 




This was a prospective study, and enrolment was from 22 January 2014 to 22 January 2016 in 
the paediatric oncology unit at Tygerberg Hospital, Cape Town, South Africa. Patients aged 0-
15 years receiving chemotherapy and who presented with fever or a history of fever were 
enrolled in the study. Informed consent was obtained from the parents/guardians (appendixes 
A, B and C) and assent from all children older than seven years (appendixes D, E and F). 
Telephonic verbal consent was accepted in cases where parents/guardians were not present at 
the time of enrolment or children were too ill to write.  
 
2.3.1 Inclusion criteria 
 
 All patients 0-15 years of age at time of presentation. 
 Fever as defined below or history of a fever before presentation. 
 Confirmed neutrophil count ≤ 500 cells/mm3. 
 All patients with a confirmed malignancy. 






2.3.2 Exclusion criteria 




 Patients older than 16 years. 
 Patients without a fever or history of a fever. 
 Patients with a neutrophil count > 500 cells/mm3. 
 Patients presenting beyond the study time period. 
 Patients without a known or confirmed malignancy. 
 
2.4 Data collection 
 
The data collected on each patient included the following: 
 
 Patient-related parameters 
o Age 
o Gender 
o Vital signs: temperature, pulse rate, respiratory rate and blood pressure 
o Nutritional status (weight and length/height) 
o Clinical focus of infection 
o Presence of comorbidities 
 Disease-related parameters 
o Presence of a CVC 
o Type of CVC 
o Type of malignancy 
o Chemotherapy regimen 
o Phase of chemotherapy 
o Number of days since last chemotherapy  
 Biomarkers 
o Hb 
o Leukocyte count 
o ANC 
o AMC 
o Platelet count 
o CRP 
o PCT 
o Blood culture result and sensitivity profile  
o Chest radiograph if performed 
o Other culture results 
 
Routine blood samples, including blood cultures, full blood count, differential WCC, CRP and 
PCT, were collected by the admitting physician. Blood cultures were obtained from peripheral 
venous or arterial sites and/or CVCs (according to National Health Laboratory Service 
guidelines – Appendix H). Based on the patient’s clinical condition and according to the 
discretion of the attending/admitting physician, other cultures and radiological investigations 
were performed.  
 
All patients were treated and monitored according to the current standard of care hospital 
protocol (Appendix I) with empiric broad-spectrum intravenous antibiotics (piperacillin-
tazobactam and amikacin).40 In cases where fever persisted beyond 48 hours despite treatment 
according to the hospital protocol, cultures and other appropriate tests were repeated and 
additional antibacterial (Vancomycin for Methicillin-resistant Staphylococcus aureus) and/or 
antifungal cover (Fluconazole) was added. All patients were evaluated daily by the attending 
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oncology team. Patients were followed up for the development of AEs until seven days after 
antimicrobial treatment had stopped or severe neutropenia had resolved while they were 
managed as inpatients. An episode was considered to have resolved once the neutrophil count 
had recovered to above 500 cells/mm3 or the patient was no longer acutely ill. More than one 
episode of FN per patient were enrolled. 
 
All chest radiographs were reported by an expert single paediatric pulmonologist.41,42 Chest 
radiographs were reported in clinical context with specific reference to type of radiographic 
change in the presence or absence of any clinical symptoms of a lower respiratory tract 
infection (LRTI). Identifying an underlying cause for abnormal radiographic changes was 




The following definitions were used at enrolment: 
 
 Fever: An axillary temperature ≥ 38.0 °C on two occasions over a 24-hour period or ≥ 
38.5 °C once.  
 Neutropenia: An ANC ≤ 500 cells/mm3.  
 CVC: Broviac catheter or external venous port. 
 Body mass index (BMI) classification according to the WHO.43 
o Severe wasting – BMI below the -3 Z-line. 
o Wasting – BMI between the -3 and -2 Z-lines. 
o Normal – BMI between the -2 and +1 Z-lines. 
o At risk of overweight – BMI between the +1 and +2 Z-lines. 
o Overweight – BMI between the +2 and +3 Z-lines. 
o Obese – BMI above the +3 Z-line. 
 Common Terminology Criteria for Adverse Events.44 
o Hb: 
 Grade 1: Hb >10 g/dL 
 Grade 2: Hb 8-10 g/dL 
 Grade 3: Hb < 8 g/dL 
 Grade 4: life threatening 
o WCC: 
 Grade 1: > 3.0 × 109/L 
 Grade 2: 2.0-3.0 × 109/L 
 Grade 3: 1.0-2.0 × 109/L 
 Grade 4: < 1.0 × 109/L 
o Platelets: 
 Grade 1: > 75.0 × 109/L 
 Grade 2: 50.0-75.0 × 109/L 
 Grade 3: 25.0-50.0 × 109/L 
 Grade 4: < 25.0 × 109/L 
 AE: SMC as a result of infection, microbiologically defined infection (MDI) and 
radiologically confirmed pneumonia (RCP). 
 
o SMC: Death, complication requiring ICU treatment and potentially life-
threatening complication as judged by the treating physician. 
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o MDI: Positive bacterial or fungal culture from a normally sterile body fluid 
compartment and detection of a viral antigen or product of polymerase chain 
reaction by a validated microbiologic method. 
o RCP: The presence of clinical symptoms and radiographic changes suggestive 
of an LRTI. 
 
2.6 Statistical analysis 
 
A statistician from Stellenbosch University was consulted to assist with data analysis. 
Microsoft Excel was used to capture individual episodes as well as the collective data. 
 
One-way analysis of variance (ANOVA) was used to test for differences in means of 
continuous measurements between the AEs and no-events groups. The usual assumptions of 
ANOVA were checked at all times and were found to be satisfactory. Summary statistics were 
reported as means and standard deviations. Sensitivity, specificity, PPV and NPV were 
calculated from cross-tabulations between the AEs groups and the scoring regime groupings. A 
significance level of 5% (p < 0.05) was used as guideline for determining significant 
differences. 
 
2.7 Ethical considerations 
 
Ethics approval was obtained from the Health Research Ethics Committee at Stellenbosch 
University on 22 January 2014. Research was subsequently conducted in accordance with 
internationally accepted ethical standards and guidelines. Each potential study participant and 
his/her parents/guardians were counselled in their first language or language of choice 
regarding the purpose, advantages and risks of participation in the study. In cases where the 
patients’ or parents/guardians’ first language was Xhosa, an interpreter was used to explain this 
information. All parents/guardians and participants were provided with an information leaflet 
in their first language (Appendix A, B, C). Informed consent (appendix D, E, F) was obtained 
from parents/guardians and assent from children older than seven years.  
 
Confidentiality was maintained by assigning a unique study number to each patient data set, 
specifying the episode number, patient number and episode per specific patient. This list was 
kept separate from the original data set. Data analysis was done anonymously using unique 
study numbers with no identifiable data present at analysis.  
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CHAPTER 3: RESULTS         
3.1 Epidemiology and overall description of episodes of febrile neutropenia  
Within the 2-year study period, a total of a 100 episodes of FN were reported in 52 patients 
with a median of 2 episodes per patient (range of 1 to 5). No episodes were excluded as strict 
inclusion criteria were followed and all patients approached for enrolment consented to 
participation. Of these, 67% of episodes occurred within seven days of completing 
chemotherapy. Median patient age for all episodes was 56 months (mean age 71 months; range 
8 to 175 months). The male:female ratio was 1.8:1. There were more patients in the second 
year of data collection with an 18% increase in FN episodes compared to the first year, with 
no clear seasonal predilection (Figure 3.1). This increase was probably due to the increased 
number of newly diagnosed children with malignancies in 2015 (n = 73) versus 2014 (n = 56).  
 
Figure 3.1: Annual and seasonal distribution of febrile neutropenia episodes  
Summer: December to February, Autumn: March to May, Winter: June to August, Spring: September to 
November  
The study population included 28 haematological malignancies and 24 solid tumours, with 
respectively 54% and 46% of FN episodes (16% in relapse malignancies) (Figure 3.2). ALL 
was the most common malignancy (15 patients, 28% FN episodes) followed by acute 
myeloblastic leukaemia (AML) in 8 patients (24% FN episodes) and lymphoma in 4 patients 
(5% FN episodes).  
The 22 patients with solid tumours included 4 patients with rhabdomyosarcoma (6% FN 
episodes), 4 patients with Ewing sarcoma (6% FN episodes), 3 patients with retinoblastoma 
(8% FN episodes), 3 patients with nephroblastoma (7% FN episodes), 3 patients with 
osteosarcoma (3% FN episodes) and 3 patients with neuroblastoma (7% of FN episodes). 
Only 2 patients (2% of FN episodes) had central nervous system (CNS) tumours (1 patient 













1st year n = 41 2nd year n = 59




Figure 3.2: Febrile neutropenia episodes (n = 100)  
ALL – acute lymphoblastic leukaemia, AML – acute myeloblastic leukaemia, HL – Hodgkin’s lymphoma, NHL 
– non-Hodgkin lymphoma 
 
Twenty-four percent of FN episodes occurred in patients with solid tumours with advanced 
disease: six episodes in a patient with Stage 4 retinoblastoma, three episodes in a patient with 
Stage 4 nephroblastoma, two episodes in two patients with Stage 4 osteosarcoma, two 
episodes in a patient with Stage 3 rhabdomyosarcoma, four episodes in three patients with 
Stage 4 rhabdomyosarcoma, six episodes in two patients with Stage 4 neuroblastoma and one 
episode in one patient with Stage 3 neuroblastoma.  
In 24 of the 100 FN episodes (24%), a CVC was in situ, including 9 internal venous ports, 14 

























Brain tumours, 2% Other, 3%
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3.2 Comorbidities  
Comorbidities were associated with 18% of the febrile episodes and included trisomy 21 in 
three patients (two AML and one pre-B-cell ALL), drug-induced dilated cardiomyopathy 
(DCMO) in two patients (nephroblastoma and Ewing sarcoma), one patient each with primary 
variable immunodeficiency (B-cell lymphoma), malignancy-associated hypertension 
(neuroblastoma), drug-induced tubulopathy (T-cell ALL), femoral deep vein thrombosis (pre-
B-cell ALL), HIV (Kaposi sarcoma) and pulmonary TB (osteosarcoma) and a patient with 
vancomycin-resistant enterococcus (VRE) gastrointestinal colonisation (AML) (Table 3.1).  
Table 3.1: Comorbidities 
Comorbidity Malignancy No of FN episodes AE 
Trisomy 21 AML 3 1 
Trisomy 21 AML 1 1 
Trisomy 21 Pre-B-cell ALL 2 1 
DCMO Nephroblastoma 2 1 
DCMO Ewing sarcoma 1 None 
Primary variable 
immunodeficiency 
B-cell ALL 1 1 
Hypertension Neuroblastoma 2 1 
Drug-induced 
tubulopathy 
T-cell ALL 1 None 
Pulmonary TB Osteosarcoma 1 None 
HIV Kaposi sarcoma 1 None 
Femoral DVT Pre-B-cell ALL 1 None 
VRE colonisation AML 2 1 
Total  18 7 
AML – acute meyloblastic leukaemia, ALL – acute lymphoblastic leukaemia, DCMO – dilated 
cardiomyopathy, TB – tuberculosis, HIV – human immunodeficiency virus, DVT – deep vein thrombosis, 








Stellenbosch University  https://scholar.sun.ac.za
14 
 
3.3 Clinical site of infection 
The FN episodes were classified (Table 3.2) as fever of unknown origin in 37% of episodes 
with one or more identifiable infectious focus in 63% of episodes. The most common clinical 
demonstrable site of infection was mucositis (15%) followed by acute gastroenteritis/typhlitis 
(12%) and URTI (11%). 
 
Table 3.2: Clinical site of infection with associated adverse event type       
 Outcome Type of adverse event 




MDI SMC RCP 
Fever of 
unknown origin 
37 10 27 8 2 2 
URTI 11 3 8 2 1 0 
LRTI 4 3 1 1 1 3 
AGE/typhlitis 12 2 10 1 1 1 
Mucositis 15 6 9 6 1 0 
Skin/soft tissue 
infection 
4 3 1 2 1 1 
CVC-related 
infection 
3 2 1 2 - - 
UTI 3 3 0 3 - - 
Other 5 3 2 3 - - 
≥ 1 site of 
infection 
6 4 2 2 1 3 
URTI – upper respiratory tract infection, LRTI – lower respiratory tract infection, AGE – acute gastroenteritis, 
CVC – central venous catheter, UTI – urinary tract infection, AE – adverse event, MDI – microbiologically 
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3.4 Adverse events  
In 40 of the 100 episodes of FN, 1 or more AE occurred, including 33 MDIs, 10 RCPs and 9 
SMCs (Figure 3.3). AEs occurred in 3 of the 4 skin/soft tissue infections, 2 of the 3 CVC-
related infections and 10 of the 37 episodes with a fever of unknown origin. In the 3 cases of 
clinical urinary tract infection, an organism was isolated. More than 1 site of infection was 
found in 6 episodes, associated with 4 AEs (Table 3.2). Only 12 of these episodes were 
associated with a CVC, including 2 episodes that presented with a clinically infected CVC site. 
 
Figure 3.3: Type of adverse event (≥ 1 adverse event/episode)  
MDI – microbiologically defined infection, SMC – severe medical complication, ALTE – acute life-threatening 
event, RCP – radiologically confirmed pneumonia 
Chest radiographs were performed in 32 of the 100 episodes based on the presence of clinical 
features suggestive of an LRTI or in episodes of fever of unknown origin. Despite 10 RCPs 
documented as AEs, clinical symptoms suggestive of an LRTI were only present in 4 patients 
on presentation with FN. Of the remaining 22 chest radiographs, only 3 were reported as normal 
with abnormalities in the lung fields noted in the rest. The abnormalities were classified as 
lobar opacification on nine radiographs, interstitial infiltrates on six radiographs and 
bronchopneumonic changes on three radiographs.  
The SMCs (Table 3.3) included two life-threatening events with four ICU admissions and three 
deaths. The three deaths included two patients classified as high risk and one patient classified 
as low risk. One patient with Stage 2 nephroblastoma with an Ammann score of 9 (high risk) 
died from septic shock due to Streptococcus mitis/oralis. The second high-risk patient with an 
Ammann score of 12 (high risk) died of lobar pneumonia associated with septic shock during 
the induction phase of AML. The low-risk patient, with an Ammann score of 7, died during 
the intensification phase of treatment for relapsed pre-B-cell ALL after developing 
gastroenteritis, multilobar pneumonia and septic shock. Pseudomonas aeruginosa was isolated 


















Type of adverse event
n = 33
n = 9 n = 10
ALTE










78 F Nephroblastoma 
Stage 3 
High Tonsillitis None Refractory septic shock, S. 
mitis/oralis bacteraemia 
29 F AML High None T21, ASD Persistent neutropenia, 









None ICU admission, refractory 
septic shock, pneumonia 
complicated by 
hypoxaemia, P. 
aeruginosa on tracheal 
aspirate 
ICU admission 
22 M Astrocytoma High Croup None UAO, candidal esophagitis 








32 F Neuroblastoma 
Stage 4 
High None Hypertension Soft tissue abscess eight 
days post admission, 
Escherichia coli 
bacteraemia, hypoxic RCP  
158 M Metastatic 
retinoblastoma, 
relapse 
High Cellulitis None Septic shock, refractory 
hypotension (inotropic 
support), polymicrobial 
bacteraemia (E. coli (2 
strains), S. aureus), 
pneumonia complicated by 
hypoxaemia 
ALTE 
29 M APL  Low AGE None Pneumonia complicated 
by hypoxaemia, chronic 
gastroenteritis, severe 
hypokalaemia 
134 M AML High AGE, 
mucositis 
None Upper gastrointestinal 
bleed, hypovolemic shock 
F – female, M – male, T21 – trisomy 21, ASD – atrial septal defect, APL – acute promeylocytic leukaemia, AGE 
– acute gastroenteritis, ALTE – acute life-threatening event, UAO – upper airway obstruction, ICU – intensive 
care unit 
3.5 Pathogens identified  
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Pathogens were isolated in 24 bacteraemias (including 4 polymicrobial bacteraemias), 3 
respiratory tract infections, 4 urinary tract infections and 2 positive skin/wound puss swabs 
(including 1 from a Broviac site). Importantly, in six of the nine ALTEs (including all four ICU 
admissions and two deaths), organisms were isolated from an otherwise sterile bodily fluid. 
The majority (58%; n = 18) were Gram-positive bacteraemias with 5 (13%) S. aureus 
(including 2 methicillin-resistant S. aureus species), 9 (23%) Streptococcus species and 3 
Enterococcus species. Gram-negative bacteraemia was detected in 41% (n = 13) episodes, 
including 3 (9%) Klebsiella pneumoniae, 4 (11%) extended-spectrum beta-lactamase-
producing K. pneumoniae and 6 (15%) E. coli isolates. Candida albicans was isolated from a 
tracheal aspirate in one FN episode that was associated with an ALTE and ICU admission. The 
microbiological organism profile and site of recovery are demonstrated in Table 3.4. 
Table 3.4: Bacterial/fungal species recovered for 100 episodes of febrile neutropenia among children with 
microbiologically defined infections according to site of the isolate 





Staphylococcus aureus  













Staphylococcus epidermidis - 1 - - - 1 
Streptococcus salivarius 2 - - - - 2 
Streptococcus oralis/mitis 4 - - - - 4 
Streptococcus vestibularis 1 - - - - 1 
Streptococcus sanguis 1 - - - - 1 
Group A beta-haemolytic Streptococcus 1 - - - - 1 
Enterococcus faecium - - 2 - - 2 
Enterococcus cloacae 1 - - - - 1 
Escherichia coli 5 - 1 - - 6 
Pseudomonas aeruginosa 2 - - 1 - 3 
Klebsiella pneumoniae 













Proteus mirabilis - - 1 - - 1 
Klebsiella oxytoca 1 - - - - 1 
Candida albicans - - - 1 - 1 
Neisseria sicca 1 - - - - 1 
Totals 
29 1 4 3 2 39 
CVC – central venous catheter, ESBL – extended-spectrum beta-lactamases producing 
3.6 Bacterial sensitivity and resistance patterns 
No. of isolates by site of recovery 
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As part of the organism profile, we also assessed the bacterial sensitivity and resistance patterns 
(Table 3.5) to assess the feasibility of an oral protocol and the efficacy of the current antibiotic 
protocol in use. Although the number of organisms isolated was too few to demonstrate any 
statistically significant pattern, it became apparent that predominantly Gram-positive 
organisms were isolated (58%). Our current empiric antibiotic protocol includes piperacillin-
tazobactam and amikacin as first-line treatment. Based on the sensitivity testing, 3 (8%) out of 
39 organisms were resistant to piperacillin-tazobactam, including 1 E. coli (3%) and 2 P. 
aeruginosa (5%) isolates. The same two P. aeruginosa isolates were also resistant to amikacin. 
Of concern, however, is the fact that the Gram-negative organisms showed extensive resistance 
to most of the standard first-line intravenous antibiotics.  
Table 3.5: Micro-organism sensitivity and resistance patterns 




























Penicillin 15 5 33 8 54 2 13 1 1 10
0 
    
Ampicillin 11 4 36 2 46 2 18 15 1 7 14 93   
Augmentin 1   1 10
0 
  10 4 40 5 50 1 10 











Cefuroxime 2 1 50     12 8 67 4 33   
Ceftazidime        8 4 50 3 38 1 12 
Cefotaxime 8 7 88 1 12   13 10 77 3 33   
Ceftriazone 6 5 83 1 17   11 8 73 3 27   
Cefipime        6 2 33 3 50 1 17 
M
L 
Erythromycin 13 9 69 4 31          
Clindamycin 12 9 75 3 25          




Ertapenem 1 1 10
0 
    6 6 10
0 
    
Meropenem        8 8 10
0 
    





Gentamycin 4   3 10
0 
  14 9 64 5 34   
Amikacin        8 6 75 1 12.
5 
1 12.5 













Pip-Taz        5 3 60 2 40   
Bactrim 8 6 75 2 25   13 4 31 9 69   




















% No. % 
Rifampicin 4 2 50 2 50          
Vancomycin 8 7 88 1 12          
Colistin        2 2 10
0 
    
Linezolid 2 2 10
0 
           
Fucidic acid 2 1 50 1 50          
ML – Macrolides, CP – Carbapenems, AGC – Aminoglycosides, Q – Quinolones. 
3.7 Categorisation of weight distribution  
The majority (65%) of episodes (30 patients) in both the high- (26%) and low- (39%) risk 
groups were in patients with a normal BMI, and 25 of the AEs occurred in this group, including 
all 3 deaths (Table 3.6). Eight AEs occurred in 11 episodes of 6 patients who were severely 
wasted, 2 AEs occurred in 7 episodes of 4 patients who were wasted, 3 AEs occurred in 10 
episodes of 5 patients who were at risk for overweight, 1 AE occurred in each of 2 overweight 
patients and 1 AE occurred in each of 2 obese patients. 
Table 3.6: Weight distribution with associated risk category and outcome (%) 




AE MDI SMC RCP 
Severely wasted 11 
 
5 6 8 6 - 2 
Wasted 7 2 5 2 2 - - 




At risk of overweight 10 4 6 3 3 - - 
Overweight 2 1 1 1 - - 1 
Obese 2 1 1 1 1 1 - 
















AE – adverse event, MDI – microbiologically defined infection, SMC – severe medical complication, RCP 
– radiologically confirmed pneumonia  
 
3.8 C-reactive protein 
For 91 episodes, the mean CRP was 118 mg/L (range of < 4 mg/L to 321.9 mg/L) while the 
CRP was not known in 9 episodes (4 of them associated with an AE). The mean CRP in the 
patients who suffered an AE, however, did not differ significantly (p = 0.42) from that of the 
patients with no AEs, with a mean CRP of 128 mg/L and 112 mg/L respectively. Only six 
episodes had a CRP of < 10 mg/L associated with three AEs. The mean CRP in the group with 
SMCs was higher at 194 mg/L as opposed to the mean of 118 mg/L and 162 mg/L in the groups 
with MDI and RCP, respectively, which was statistically significant (p = 0.02). There was no 
statistically significant difference in CRP value between the high- and low-risk groups 
according to the Ammann rule (p = 0.21). 
 
 
3.9 Haematological toxicity grading 
The haematological grading of chemotherapy toxicity44 (Table 3.7) showed a 75% Grade 4 
toxicity for total WCC, a 53% Grade 3 toxicity for Hb and a 35% Grade 4 toxicity for platelets. 
The mean WCC was 0.83 × 109/L for all episodes and 0.53 × 109/L in episodes with an 
associated AE. The mean Hb for all episodes was 8.1 g/dL and 8.2 g/dL in episodes with a 
reported AE. The mean AMC was 0.17 × 109/L compared to 0.08 × 109/L in episodes 
associated with an AE. The AMC could not be measured in two episodes due to the total WCC 
being too low. 
Unknown 3 1 2 2 1 1 - 
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Table 3.7: Haematological grade of toxicity according to the Common Terminology Criteria for Adverse 
Events and parameters44 
 Toxicity grade     














19% 28% 53% - 4.4-18.2 6.6-9.4 8.1 8.2 
WCC 
(× 109/L) 
3% 12% 10% 75% 0.04-5.25 0.23-0.99 0.83 0.53 
ANC 
(× 109/L)  
   100% 0.0-0.5 0.04-0.16 0.07  
AMC 
(× 109/L) 
    0.0-2.08 0.01-0.16 0.17 0.08 
Plt 
(× 109/L) 
38% 9% 18% 35% 3-453 15-122 81 61 
Hb – haemoglobin, WCC – white cell count, ANC – absolute neutrophil count, AMC – absolute monocyte count, 
Plt – platelets, AE – adverse event. 
 
 
3.10 Individual variables 
Assessment of the predictive value of individual variables for an AE (Table 3.8) showed that 
only total WCC and AMC achieved statistical significance with a respective p-value of < 0.01 
and 0.05, with univariate analysis. Other variables assessed included age (p = 0.18), BMI (p = 
0.64), sex (p = 0.77), temperature (p = 0.69), Hb (p = 0.7), platelets (p = 0.08) and CRP (p = 
0.42). With multivariate analysis only BMI (p = 0.03) and Temperature (p = 0.02) achieved 
statistival significance.  
Table 3.8: Performance of individual variables in predicting adverse events  
 AE group (n) Non-AE group (n) p-value 
Age (months) - mean 63 76 0.18 
BMI (SD) - mean 1.8 1.9 0.64 
Sex (male) 31 45 0.77 
Temperature (°C) - 
mean 
38 37.8  0.69 
WCC (× 109/L) - 
mean 
0.53 1.02 < 0.01 
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AMC (× 109/L) - mean 
(excluding 2 episodes 
with unknown AMC) 
0.08 0.23 0.05 
Hb (g/dL) - mean 8.2 8.0 0.7 
Platelets (× 109/L) - 
mean 
61 94 0.08 
CRP (mg/L) 128 112 0.42 
AE – adverse event, BMI – body mass index, WCC – white cell count, AMC – absolute monocyte count, Hb 
– haemoglobin, CRP – C-reactive protein 
 
 
3.11 Validation of the Ammann tool 
By applying the Ammann tool12 to our study population, 43% of episodes were classified as 
high risk with 22 AEs occurring in this group, including 2 deaths. The other 18 AEs occurred 
in the 57% of patients assessed as being at a low risk of suffering an AE and included 1 of the 
3 deaths. Applying the calculation used in both the other cohorts the rule achieved a sensitivity 
of 56.8% (95% CI 39.5% – 72.9%), specificity of 65% (95% CI 51.6% - 76.9%), PPV 50% 
95% CI 34.2% - 65.8%) and a NPV of 70.9% (95% CI 34.2% - 65.8%) at reassessment (3 AEs 
known). Because we were interested in applying the tool at presentation to plan future 
management we also calculated sensitivity, specificity, PPV and NPV at presentation. 
Applying the tool at prestation yielded a sensitivity of 55%  and a specificity of 65% with  a 
PPV of 51%  and the NPV in our cohort of 68% (again no correlation with both Ammann et 
al12 and Miedema et al31) (Table 3.9). 
 
Table 3.9: Performance of the Ammann rule applied to the three different cohorts 
 Our cohort Ammann 
et al12 











Sensitivity 55% 56.8% 92% 69% 82% 
Specificity 65% 65% 45% 57% 57% 
PPV 51% 50% 40% 34% 23% 
NPV 68% 70.9% 93% 85% 91% 
PPV – positive predictive value, NPV – negative predictive value 
 
 
3.12 Comparison of cohorts 
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To determine the reasons for the differences in sensitivity and specificity, we compared our 
cohort to the Ammann12 and Miedema cohorts31 (Table 3.10) and found that our cohort was 
younger with a median age of 4.7 years compared to 6.9 years for the Ammann cohort1 and 6.6 
years for the Miedema cohort31. All three cohorts had a male predominance and similar 
incidence of both AML (15% in our study population, 11% in the population of Ammann et 
al12 and 13% in the population of Miedema et al31) and lymphoma (8% in our study population, 
8% in the population of Ammann et al12 and 12% in the population of Miedema et al31). ALL 
was diagnosed in 29% of our cohort, which was lower than the 44% in the cohort of Ammann 
et al12 and 37% in the cohort of Miedema et al.31 Solid tumours outside the CNS represented 
44% of episodes in our cohort, higher when compared to 26% in both the Ammann12 and 
Miedema31 cohorts. CNS tumours were diagnosed in only 4% of episodes in our cohort, 
compared to 11% and 12% in the Ammann1 and Miedema31 cohorts, respectively.   
Our cohort had more episodes classified as low risk (57%) compared to 35% in the Ammann 
cohort12 as well as more AEs in 40% of FN episodes versus 29% in the Ammann cohort12 and 
24% in the Miedema cohort.31 Included in the AEs were more SMCs (9%) compared to the 
cohort of Ammann et al12 with 4.9% and that of Miedema et al31 with 4.7% as well as more 
MDIs (31%) compared to 22% in the Ammann cohort12 and 22% in the Miedema cohort31 but 
similar RCP (10%) compared to the cohort of Ammann et al12 (8.5%). Bacteraemia was also 
higher in 46% of low-risk FN episodes in our cohort compared to 7% of episodes in the 
Ammann cohort.31 Gram-positive organisms were predominantly isolated in all three cohorts 
(18% in our cohort vs. 9.9% in the Ammann12 cohort and 10% in the Miedema31 cohort).  
AEs were known in 3 episodes at presentation in our cohort compared to 30 episodes known 
in the Ammann cohort12. A further 2 episodes were known at reassessment in our cohort 
compared to 65 in the Ammann cohort12 and 21 in the Miedema cohort.31 Included in the SMCs 
were three deaths in our cohort, which was similar to three deaths in the Ammann cohort.12  
Table 3.10: Comparison of the three cohorts 
 Our cohort Ammann et al12 Miedema et al31 
 No. % No. % No. % 
FN episodes 100  423  210  
Patients 52  206  110  
Median age  
(years) 
4.7 years  6.9 years  6.6 years  
Male patients 34 65 116 56 63 57 
Type of cancer       
     ALL 15 29 90 44 41 37 
    AML 8 15 23 11 14 13 
    Lymphoma 4 8 16 8 13 12 
    CNS 2 4 23 11 13 12 
    Solid tumour           
outside the CNS 
23 44 54 26 29 26 
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Median no. of FN 
episodes/patient 
2  2  1  
     Range 1-5  1-10  1-13  
High risk 
(Ammann rule) 
43 43  75   
Low risk 
(Ammann rule) 
57 57  35   







4.9 10 4.7 
MDI 31 31 94 22 46 22 
  Bacteraemia 24 24 67 15.8 32 15 
 Bacteraemias in  
low-risk episodes 
 46  7  29 
Gram positive 18 18 42 9.9 22 10 
     S. aureus 4  
(including 1 
MRSA) 
 4    
     Coagulase-
negative 
staphylococci 
1  16  9  
     S. mitis 4  12  8  
     Other 7  14  7  
     Gram                                       
negative 
13 13 27 6.3 11 5.2 
     E. coli 2  15  3  
     P. aeruginosa 2  6  3  
    K. pneumoniae 6  
(including 3 
ESBL) 
   2  
     Other 3  6  3  
Polymicrobial 
infection 
3 3 5  5 2.3 
RCP 10 10 36 8.5 13 6.1 
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AE known at 
presentation 
3  30    
AE known at 
reassessment 
5  65  21  
FN – febrile neutropenia, ALL – acute lymphoblastic leukaemia, AML – acute meyloblastic leukaemia, CNS – central nervous system, AE – 
adverse event, SMC – severe medical complications, MDI – microbiologically defined infection, RCP – radiologically confirmed pneumonia  
3.13 Validation of other risk assessment tools 
We thereafter applied the Rackoff,21 Baorto,22 Rondinelli27 and Santolaya24,25 rules to our 
patient population to determine whether these could possibly be used to identify a low-risk 
group. A limitation, however, was the inclusion and exclusion criteria, which could not be 
applied strictly as there is great variability in the definitions used by the different authors. By 
applying the Rackoff rule,21 9 episodes were classified as high risk, 61 as mild risk and 28 as 
low risk while 2 episodes were excluded due to unknown AMC. AEs occurred in 5 high-risk 
episodes, 25 mild-risk episodes and 10 low-risk episodes. To calculate a sensitivity and 
specificity, the intermediate- and high-risk groups were combined as the goal of the study was 
to identify a group at minimal risk of an AE; this yielded a sensitivity of 75% and a specificity 
of 31%. 
The Baorto rule21 had a similar performance with 68 episodes identified as high risk (30 AE) 
and 26 as low risk (8 AE), with a sensitivity of 79% and a specificity 32%. Based on the 
exclusion criteria, 4 episodes were excluded as the patient’s age was below 12 months, with 
another 2 episodes excluded as the AMC was not known.  
The Rondinelli rule27 only included the first FN episode in its calculation of a risk assessment 
score, and therefore only 52 episodes qualified for inclusion. By applying the rule, 2 episodes 
were classified as high risk, 10 as intermediate risk and 40 as low risk, with respectively 1, 6 
and 15 AEs per group. Again, the high- and intermediate-risk groups were combined to 
calculate the sensitivity, which was 32%, and the specificity, which was 83%. 
The Santolaya rule24,25 had a similar performance, achieving a sensitivity of 68% and a 
specificity of 37%. AEs occurred in 27 of the 68 high-risk episodes and in 13 of the 32 low-
risk episodes. We therefore could not achieve an adequate sensitivity or specificity for any of 
these rules to be applied in clinical practice. Table 11 shows the sensitivity and specificity 
achieved by applying these rules to our cohort.  











Sens Spec NPV PPV 
Rules predicting bacteraemia 
Rackoff et al20 30 40 10 18 0.75 0.31 0.64 0.43 
Baorto et al21 30 38 8 18 0.79 0.32 0.69 0.44 
Rules predicting severe/invasive bacterial infection 
Rondinelli et al27 7 5 15 25 0.32 0.83 0.63 0.58 
Santolaya et al24,25 27 41 13 19 0.68 0.37 0.59 0.40 
TP – true positive, FP – false positive, FN – false negative, TN – true negative, NPV – negative predictive 
value, PPV – positive predictive value   
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Chapter 4: DISCUSSION         
4.1 Discussion 
This study aimed to validate a risk assessment tool published by Ammann et al1 that could 
potentially lead to the identification of a patient population at low risk of suffering an AE during 
an episode of FN. In the derivation and validation of the Ammann tool,12 the predefined 
sensitivity was established at ≥ 90%, which was achieved in the researchers’ cohort at 92% 
with an associated 45% specificity, 93% NPV and 40% PPV.1 This was a similar finding to 
that reported by Miedema et al,31 who also attempted to validate the Ammann rule in a Dutch 
cohort in 2011 but could only achieve a sensitivity of 82% with a specificity of 57%. Miedema 
et al proposed that differences in chemotherapy treatment protocols, genetic factors and 
microbiological environments as well as retrospective collection of their data might be possible 
reasons for the lower sensitivity.31  
In this study, the tool was applied prospectively but also yielded significantly lower sensitivity 
of 55%, specificity of 65%, PPV of 51% and NPV of 68%. This might be explained by the 
younger age group (4.7 years versus 6.9 years12), more severe medical conditions (9% versus 
4.9 %12) and higher bacteraemia (24% versus 15.9%12). The Rondinelli rule27 is one of the risk 
assessment models that include age in its score, with an age of less than five years being 
associated with an increased risk of SICs, bacteraemia and death (p = 0.001).27 Even though 
the age group in this study was younger than the Ammann cohort,1 age failed to achieve 
statistical significant association with an AE (p = 0.18). 
Ammann et al12 reported only a 7% bacteraemia rate in their low-risk population, while it was 
46% in this study. One of the SMCs that resulted in death occurred in the low-risk group in this 
study population, which was similar to the study by Ammann et al,12 who also reported two 
deaths in patients assessed as low risk at the onset of FN. Other differences included a lower 
mean Hb level and a higher occurrence of antibiotic-resistant organisms. CNS tumours were 
more common in the European cohorts.12,31 All three cohorts showed a male predominance. 
Mortality was higher in this study population (3%) compared to the Ammann cohort (0.7%).12  
We also demonstrated a higher frequency of FN in solid tumours outside the CNS. There were 
more FN episodes in relapsed malignancies (16%) as well as advanced disease (24%) in this 
study, which supports the findings of Stones et al that advanced stage of disease contributes to 
a poorer outcome and higher incidence of AEs.13 The mean Hb in our cohort was 8.1 g/dL, 
lower than the Hb ≥ 9g/dL used as the highest weighted score in the Ammann rule12 whereby 
higher Hb as a risk factor might reflect the need for a blood transfusion prior to presentation 
with FN.12 By grading the haematological toxicity of chemotherapy in our patients, we 
demonstrated that the majority had severe bone marrow suppression at the time of presentation 
(75% Grade 4 toxicity for WCC, 53% Grade 3 toxicity for Hb and 35% Grade 4 toxicity for 
platelets), which could contribute to the increased occurrence of AEs with a higher mortality 
rate. The American Society of Clinical Oncology recommended the use of granulocyte colony-
stimulating factor for primary prophylaxis in patients with a high likelihood of FN and as 
secondary prophylaxis for high-risk patients,45 based on a meta-analysis that found a 20% 
reduction in FN and a shorter hospitalisation duration associated with its use.46 Ozkaynak et al 
found a reduction in the number of days of neutropenia, fever and hospitalisation.47 The use of 
granulocyte colony-stimulating factor was, however, restricted in our cohort and reserved for 
severe cases of prolonged neutropenia due to limited resources. This could possibly contribute 
to the higher frequency (40% vs. 29%12 and 24%31) and late occurrence (after reassessment) of 
AEs.  
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CRP was the only biomarker of infection routinely available at our institution for identification 
of bacterial infection and was of limited value, with a high CRP found in both AE and non-AE 
groups (mean CRP 128 mg/L and 112 mg/L, respectively; p = 0.42). This was in keeping with 
the findings of Miedema et al37 who also demonstrated a minimal difference in median CRP 
levels in patients with or without bacteraemia (p = 0.183) with low sensitivity and specificity 
in distinguishing bacterial causes of fever from other causes. The researchers concluded that a 
combination of IL-8 and PCT levels could achieve a sensitivity of 100%.37 In a study conducted 
by Secmeer et al,36 they could also only demonstrate a sensitivity of 66.7% in the use of CRP 
to predict bacteraemia in paediatric FN neutropenia, using a CRP cutoff value of 50 mg/L.36 In 
contrast, Mian et al39 showed a significant difference in median CRP levels in high-risk versus 
low-risk FN episodes (170 mg/L vs. 38 mg/L) and that a CRP >100 mg/L achieved an 88% 
sensitivity in predicting FN episodes at high risk of prolonged hospitalisation, ICU admission 
and MDI.39 A CRP of 178.7 mg/L was shown to be the optimal cutoff value to predict AEs in 
our patient population with a sensitivity of 71% and a specificity of 83%. 
It has been demonstrated that a poor nutritional status contributes to more severe chemotherapy 
toxicity and a worse long-term outcome in paediatric oncology patients.48-51 Specifically, 
sustained overweight or underweight status during intensive phases of high-risk ALL treatment 
has been associated with a significantly greater risk for relapse, death or the development of 
treatment-related toxicity.52 We found that most of our patients were within the normal limits 
according to the WHO classification43 of nutritional status and could therefore not demonstrate 
a statistically significant association between nutritional status and the occurrence of AEs. A 
limitation of the study was the lack of data for mid-upper arm circumference or triceps skinfold 
thickness as measures of malnutrition, which might be more sensitive indicators of malnutrition 
in paediatric oncology.53 
Total WCC (p < 0.01) and AMC (p = 0.05) were the only variables that reached statistical 
significance in their independent association with AEs in our cohort, which is in keeping with 
the findings of both Rackoff et al20 and Baorto et al21 in the derivation of their independent 
rules. The Rackoff rule categorised patients into three categories according to their AMC and 
temperature at presentation and predicted bacteraemia with a 100% sensitivity and 23.2% 
specificity.20 When applied to our patient population, the Rackoff rule20 achieved a 42.9% 
sensitivity and a 64.3% specificity as opposed to the 87% sensitivity and 49% specificity 
achieved by Ammann et al applying the same rule to their cohort.12 Baorto et al21 modified the 
Rackoff rule20 using only a monocyte count of ≥ 0.155 × 109/L as a predictor of bacteraemia 
with a sensitivity and specificity of 88.9% and 22.4%, respectively.21 Again, this could not be 
achieved in this study population with a sensitivity of 43.7% and a specificity of 66.7% for the 
Baorto rule. 21   
The bacterial organism profile of this study group was similar to that of the studies by Ammann 
et al12 and Miedeman et al,31 namely predominantly Gram-positive bacteraemia (73%). 
Coagulase-negative Staphylococcus species was the most common gram-positive organism 
isolated in both the Ammann12 (n = 16) and Miedema31 (n = 9) cohorts, which was in contrast 
to our study population, with Streptococcus viridans (20%) being the most common organism. 
We also documented a higher rate of gram-negative antibiotic-resistant organisms, including 
four extended-spectrum beta-lactamase-producing K. pneumoniae (10%), two methicillin-
resistant S. aureus (5%) and one P. aeruginosa (3%) sensitive only to colistin, while no specific 
resistance patterns were reported in the Ammann12 or Miedema31 cohorts. The use of 
ciprofloxacin prophylaxis in the Miedema et al study54 showed increased ciprofloxacin 
resistance in some centres. Ciprofloxacin use is not standard practice at our institution and 
therefore limited ciprofloxacin resistance (8%) was demonstrated. Because of the small size of 
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our cohort, it was not possible to determine whether this observed increased resistance pattern 
was of statistical significance. Resistance to piperacillin-tazobactam was documented in three 
organisms (8%) (one E. coli and two P. aeruginosa) in our cohort, with amikacin resistance in 
the same two P. aeruginosa (5%) isolates. Based on the above results, the current empirical 
antibiotic protocol that includes the use of piperacillin-tazobactam and amikacin as first-line 
treatment should adequately treat almost 85% (36 of 39) of MDIs.  
4.2 Study strengths and limitations 
 
 Data collected prospectively relied on the availability and quality of clinical records 
created by the admitting physicians and was subject to their choice of words and 
descriptive terms, thus necessitating conclusions to be drawn and making the data less 
reliable. 
 The outcome of each episode was followed up and documented on a prospective basis, 
which improved the accuracy and comprehensiveness of the data. 
 
4.3 Conclusion and recommendations 
 
In conclusion, although this study has not succeeded in validating the Ammann tool,12 it 
demonstrated the important significant association between total WCC and AMC in an AE 
during FN. The study also demonstrated the marked differences in patient cohorts between 
high-income countries versus a low- to middle-income country, especially with regard to 
median patient age, frequency of FN episodes in solid tumours excluding the CNS as well as 
the frequent occurrence of antibiotic-resistant bacteraemia. Future studies should include 
additional biomarkers such as the use of PCT to assist with differentiating between high-risk 
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Appendix A: Parental informed consent form 
PARENT/GUARDIAN INFORMATION LEAFLET AND INFORMED CONSENT 
FORM FOR CHILDREN 0-15 YEARS FOR CLINICAL STUDY   
1. STUDY TITLE 
Predicting the Risk of Adverse Events in Children with Febrile Neutropenia: a validation of 
previously identified clinical decision rules.  
2. INTRODUCTION   
Your child has been invited to take part in a research study.  The information on this page is to 
help you decide whether your child will take part.  Before you agree to take part in this study 
you should fully understand what it is about.  If you have any questions, which are not fully 
explained on this page, do not hesitate to ask the study doctor.  
3. WHY IS THIS STUDY DONE?  
Fever is one of the complications of chemotherapy for cancer. Because chemotherapy 
decreases your child’s ability to fight infection it can cause him/her to become very ill. But 
infection is not the only cause for fever it can also be the result of the chemotherapy or cancer 
itself. The aim of this study is to identify factors that could predict serious life threatening 
infections in children receiving chemotherapy for cancer who also develop a fever. The 
information obtained will be used to set up a list of factors to predict which patients will be 
sicker than others. This information will also be used to possibly change monitoring and 
treatment of children with cancer and fever. 
4. EXPLANATION OF PROCEDURES TO BE FOLLOWED 
This  study  involves  answering  some  questions  with  regards  to  your  child’s  illness, 
clinical findings on physical examination and some blood tests. The blood tests will be the 
same tests routinely done and thus no additional blood samples will need to be collected. The 
information and results of the blood tests will be captured on a datasheet with a specific study 
number.  
5. HAS THE STUDY RECEIVED ETHICAL APPROVAL? 
This clinical study protocol was submitted to the Faculty of Health Sciences Research Ethics 
Committee, University of Stellenbosch and written approval has been granted by that 
committee.  
6. WHAT ARE YOUR CHILD’S RIGHTS AS A PARTICIPANT IN THIS STUDY? 
Your child’s participation in this study is entirely voluntary and you can refuse for him/her to 
take part or withdraw at any time without stating any reason.  Your withdrawal will not affect 
your child’s access to continue/other medical care.   
 
7. WILL ANY OF THESE STUDY PROCEDURES RESULT IN DISCOMFORT OR 
INCONVENIENCE? 
Vena puncture (i.e. drawing blood) are normally done as part of his/her routine medical care 
and present a slight risk of discomfort.  Drawing blood may result in a bruise at the puncture 
site, or less commonly swelling of the vein or bleeding from the puncture site.  Your child’s 
protection is that the procedures are performed under sterile conditions by experienced 
personnel. 
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8. WHAT ARE THE RISKS INVOLVED IN THIS STUDY?  
This study will not test any new drugs or procedures so there is no risk related to the study 
itself. If the tests done show results that are important for the care of the child that information 
will be given to you and the doctor taking care of your child. 
9. CONFIDENTIALITY 
All information obtained during the course of this study is strictly confidential.  Data that may 
be reported in scientific journals will not include any information which identifies your child 
as a patient in this study. Any information uncovered regarding your child’s test results or state 
of health as a result of your child’s participation in this study will be held in strict confidence.  
You will be informed of any finding of importance to your child’s health or continued 
participation in this study. If you have any questions regarding the research study, its aims or 
procedures you can contact Dr Green or Dr van Zyl at the Tygerberg G3 oncology unit at 021 
938 4564. If you have questions regarding your child’s rights as a research subject, contact Ms 
Maléne Fouché [mfouche@sun.ac.za; 021 808 4622] at the Division for Research 
Development.  
INFORMED CONSENT FOR PARENTS / GUARDIANS (On behalf of minors under 15 
years old) I ...………………… hereby confirm that I have been informed by the investigator, 
Dr ……..…….……… about the nature, conduct, benefits and risks of this clinical study.  I 
have also received, read and understood the above written information (Patient Information 
Leaflet and Informed Consent) regarding the clinical study.  I am aware that the results of the 
study, including my child’s personal details regarding date of birth, initials and diagnosis will 
be anonymously processed into a study report. I may, at any stage, without prejudice, withdraw 
my consent for my child’s participation in the study.  I have had sufficient opportunity to ask 
questions and (of my own free will) declare my child prepared to participate in the study.   
.......................................................                ........................................................... 
Parent/Guardian(s) name                              Parent/Guardian(s) signature 
Date............................................... 
 
.......................................................                ........................................................... 
Patient's name                                                 Patient’s signature 
Date............................................... 
 
.......................................................               ............................................................. 
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Appendix B: Ouertoestemming 
 
OUER/VOOG INLIGTINGSTUK EN INGELIGTE TOESTEMMING VIR KINDERS 
0-15 JAAR VIR DIE KLINIESE STUDIE.  
1. STUDIE TITEL 
Predicting the Risk of Adverse Events in Children with Febrile Neutropenia: a validation of 
previously identified clinical decision rules  
2. INLEIDING 
Jou kind is genooi om te deel te neem aan ons navorsingstudie. Die inligting op hierdie bladsy 
is om jou te help om te besluit of jou kind wat tans siek is, mag deelneem. Voordat u instem 
om deel te neem in hierdie studie moet u ten volle verstaan waaroor die studie gaan. As u enige 
vrae het, moet asseblief nie huiwer om die studiedokter te vra nie. 
3. HOEKOM WORD DIE STUDIE GEDOEN? 
Koors is een van die gevolge van kankerbehandeling (chemoterapie). Koors kan die gevolg 
van chemoterapie, die kanker self of infeksie wees. Omdat chemoterapie jou kind se vermoë 
om infeksie te beveg verminder kan dit veroorsaak dat hy/sy baie siek word. Die doel van 
hierdie studie is om faktore te identifiseer wat ernstige lewensbedreigende infeksies voorspel 
in kinders wat chemoterapie vir kanker ontvang en 'n koors ontwikkel. Die inligting wat verkry 
word, sal gebruik word om 'n lys van faktore op te stel wat moontlik sal voorspel watter kinders 
sieker sal wees as ander. Hierdie inligting sal ook gebruik word om moontlik die monitering 
en behandeling van kinders met kanker en koors te verander. 
4. PROSEDURES WAT GEVOLG GAAN WORD. 
Hierdie studie behels die antwoord van 'n paar vrae met betrekking tot jou kind se siekte, 
kliniese bevindinge op fisiese ondersoek en resultate van bloedtoetse. Die bloedtoetse sal 
dieselfde toetse wees wat vir opname en behandeling gedoen word. Geen bykomende 
bloedmonsters sal versamel word nie. Die inligting en resultate van die bloedtoetse sal op ‘n 
datavorm met 'n spesifieke studie nommer ingevul word.  
5. ETIESE GOEDKEURING. 
Die kliniese studieprotokol is aan die Fakulteit Gesondheidswetenskappe se navorsings-
etiekkomitee van die Universiteit van Stellenbosch gestuur en skriftelike toestemming is deur 
hierdie komitee toegestaan. 
6. WAT IS U KIND SE REG AS DEELNEMER AAN DIE STUDIE? 
U kind se deelname aan hierdie studie is heeltemal vrywillig en u kan weier dat hy/sy deelneem 
of u kan enige tyd sonder rede onttrek. Jou onttrekking sal geen invloed op jou kind se 
voortgesette mediese sorg hê nie. 
7. KAN ENIGE VAN DIE PROSEDURES ONGEMAK OF ONGERIEF VEROORSAAK? 
Venapunksie (dws om bloed te trek) word gewoonlik gedoen as deel van u kind se roetine 
mediese sorg en bied 'n risiko van ongemak. Om bloed te trek kan lei tot 'n kneusing (blou kol) 
op die punksie area, of minder algemeen swelling van die aar of bloeding van die punksie area. 
Jou kind se beskerming is dat die prosedures uitgevoer word onder steriele omstandighede deur 
ervare personeel. Slegs die roetine toetse sal gedoen word – dws GEEN addisionele 
bloedmonsters sal geneem word nie. 
 
8. WAT IS DIE RISIKO VIR U KIND AS DEELNEMER VAN DIE STUDIE? 
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Hierdie studie sluit NIE die toets van enige nuwe medisyne of prosedures in nie, so daar is geen 
risiko verbonde aan die studie self nie. As die toetse gedoen enige resultate belangrik vir die 
versorging van u kind toon, sal die inligting aan u gegee word deur die dokter wat na u kind 
omsien. 
9. VERTROULIKHEID. 
Alle inligting wat in die loop van hierdie studie vesamel word, is streng vertroulik. Data wat 
moontlik in wetenskaplike tydskrifte berig word, sal nie enige inligting insluit wat u kind as ‘n 
pasiënt in hierdie studie kan identifiseer nie. Enige inligting rakende u kind se toetsuitslae of 
staat van gesondheid sal streng vertroulik hanteer word. U sal in kennis gestel word van enige 
bevinding van belang vir u kind se gesondheid of behandeling. As jy enige vrae oor die 
navorsing, sy doelwitte of prosedures het kan jy Dr Green of Dr van Zyl by die Tygerberg G3 
onkologie-eenheid by 021 938 4564 kontak. As jy enige vrae het oor jou kind se regte as 'n 
studiedeelnemer, kontak me Maléne Fouché [mfouche@sun.ac.za; 021 808 4622] by die 
Afdeling Navorsingsontwikkeling.  
INGELIGTE TOESTEMMING VIR OUERS / VOOGDE (Namens minderjariges onder 
15 jaar) Ek (……………………) bevestig hiermee dat ek ingelig is deur die ondersoeker, dr 
................ oor die aard, optrede, voordele en risiko's van hierdie kliniese studie. Ek het ook 
(ontvang, gelees en verstaan) die bogenoemde skriftelike inligting ten opsigte van die kliniese 
studie ontvang, gelees en verstaan. Ek is bewus daarvan dat die resultate van die studie, 
insluitend my kind se persoonlike besonderhede met betrekking tot die datum van geboorte, 
voorletters en diagnose anoniem verwerk sal word in 'n studieverslag. Ek kan in enige stadium, 
sonder vooroordeel, my toestemming vir my kind se deelname aan die studie onttrek. Ek het 
voldoende geleentheid gekry om vrae te vra en (van my eie vrye wil) gee ek toestemming dat 
my kind mag deelneem aan die studie. 
.....................................................  .................................................. ......... 
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Appendix C Xhosa parental consent 
Isihlomelo C: Uxwebhu lwemvume efanelekileyo yomzali. 
IPHETSHANA LEENKCUKACHA ZOMZALI/ZOMNTU OKHULISA UMNTWANA 
NGOKUSEMTHETHWENI KUNYE NOXWEBHU LWEMVUME 
EFANELEKILEYO YABANTWANA ABASUSELA KWI-0-15 LEMINYAKA 
UBUDALA KUPHANDO LWEZONYANGO   
10. ISIHLOKO SOPHANDO 
Xa sithekelela uMngcipheko weZiganeko eziNgathandekiyo kuBantwana abanesifo esiyi-
Febrile Neutropenia: IMigaqo yeSiqinisekiso seSigqibo esenziwa Ngaphambili kuNyango (A 
Validation of Previously Identified Clinical Decision Rules.)  
11. INTSHAYELELO   
Umntwana wakho umenyiwe ukuba athathe inxaxheba kuphando lwesifundo. Iinkcukacha 
ezikweli phepha zezokukunceda ukuba wenze isigqibo ngokuba ingaba umntwana wakho uza 
kuthatha inxaxheba kolu phando kusini na. Phambi kokuba uvume ukuthatha inxaxheba kolu 
phando kufuneka uqonde ngokupheleleyo ukuba lumalunga nantoni na. Ukuba unemibuzo, 
engacaciswanga ngokupheleleyo kweli phepha, ungathandabuzi ukubuza ugqirha wophando.  
12. LWENZELWA NTONI OLU PHANDO?  
Ifiva sesinye sezigulo ezinobucukubhede xa kusenziwa unyango lomhlaza ngokutshisa 
ngoomatshini ikhimotheraphi. Ngenxa yokuba ikhimotheraphi icutha amandla omntwana 
wakho okulwa nolosuleleko zizifo oko kungambangela ukuba agule kakhulu. Kodwa 
ulosuleleko zizifo ayikokuphela konobangela wefiva kusenokuba sisiphumo sekhimotheraphi 
okanye somhlaza ngokwawo. Injongo yolu phando kukuchonga iimpawu ezinokukhokelela 
kulosuleleko zizifo eziyingozi emandla ebomini babantwana abafumana unyango 
lwekhimotheraphi kwisifo somhlaza nothi abe nefiva. Iinkcukacha ezifunyenweyo ziya 
kusetyenziselwa ukuqulunqa uluhlu lwempawu ezinkuthekelelwa ukuba zizo ezinokubonisa 
ukuba ziziphi izigulana eziya kugula kakhulu kunezinye. Kananjalo ezi nkcukacha ziya 
kusetyenziselwa mhlawumbe ukutshintsha indlela abajongwa ngayo nabanyangwa ngayo 
abantwana abanomhlaza nefiva. 
13. INGCACISO YEENKQUBO EZIZA KULANDELWA 
Olu phando luquka ukuphendula imibuzo ethile ephathelene nokugula komntwana wakho, 
iziphumo zonyango zohlolo lomzimba nezinye iimvavanyo zegazi. Iimvavanyo zegazi ziya 
kuba ziimvavanyo ezifanayo ezenziwa ngokwesiqhelo kwaye ke ngenxa yoko akusayi 
kufunwa zisampuli zongeziweyo zegazi. 
Iinkcukacha neziphumo zazo zonke iimvavanyo zegazi ziya kugcinwa kuvimba weenkcukacha 
onenombolo ethile yophando.  
14. INGABA OLU PHANDO LUSIFUMENE ISIPHUMEZO SOKWAMKELEKA 
NGOKWEENQOBO EZISESIKWENI? 
Le migaqo yophando lwezonyango yangeniswa kwiKomiti yeeNqobo ezisesikweni ngoPhando 
yeCandelo lobuNzululwazi ngezeMpilo, kwiYunivesithi yase-Stellenbosch kwaye 
kwanikezelwa isiphumezo esibhaliweyo yile komiti.  
15. NGAWAPHI AMALUNGELO OMNTWANA WAKHO NJENGOMTHATHI-
NXAXHEBA KOLU PHANDO? 
Ukuthatha inxaxheba komntwana wakho kolu phando kwenziwa ngokuzithandela 
ngokupheleleyo kwaye unelungelo lokungavumi ukuba athathe inxaxheba okanye 
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ungamkhupha nanini na ngaphandle kokubeka isizathu soko. Ukurhoxa kwakho akusayi 
kuchaphazela indlela yokufikelela komntwana wakho kunyango lwamayeza oluqhubekayo 
okanye kolunye unyango.   
16. INGABA KUKHO INKQUBO KWEZI ZOLU PHANDO ENOKUKHOKHELELA 
EKUBENI UNGAZIVA KAKUHLE OKANYE UPHAZAMISEKE? 
I-Vena puncture (umzekelo: ukutsalwa kwegazi) kudla ngokwenziwa ngokuyinxalenye 
yonyango lwakhe lwesiqhelo kwaye kwenza ungaziva kakuhle kancinane nje. Ukutsalwa 
kwegazi kungakhokelela ekubeni nomtshithana kule ndawo bekutsalwa kuyo igazi, okanye 
ukudumba okuncinane okuqhelekileyo komthambo okanye ukopha kule ndawo bekutsalwa 
kuyo igazi. Ukhuseleko lomntwana wakho kukuba ezi nkqubo zenziwa phantsi kweemeko 
engenantsholongwane kwaye isenziwa ngabasebenzi abanamava. 
17. YIYIPHI IMINGCIPHEKO EBANDAKANYEKA KOLU PHANDO?  
Olu phando alusayi kuvavanya nawaphi amachiza amatsha okanye iinkqubo ezintsha ngoko ke 
akukho mngcipheko onxulumene nophando olu ngokwalo. Ukuba iimvavanyo ezenziweyo 
zibonakalisa iziphumo ezibalulekileyo ekukhathalelweni komntwana ezi nkcukacha ziya 
kunikezelwa kuwe nogqirha onyanga umntwana wakho. 
18. UKUGCINWA KWEENKCUKACHA ZIYIMFIHLO 
Zonke iinkcukacha ezifunyenwe ngexesha lolu phando ziya kugcinwa ziyimfihlo 
ngokumandla. Iinkcukacha ezinokukhankanywa kumaphepha-ndaba obunzululwazi azisayi 
kubandakanya zaziphi iinkcukacha ezinokwalatha umntwana wakho njengesigulana kolu 
phando. Naziphi iinkcukacha ezingajongwanga ngokuphathelene neziphumo zovavanyo 
okanye nemeko yempilo yomntwana wakho ngenxa yokuthatha inxaxheba komntwana wakho 
kolu phando ziya kugcinwa ziyimfihlo ngokumandla. Uya kwaziswa ngazo naziphi iziphumo 
ezibalulekileyo ngempilo yomntwana wakho okanye ngokuqhubeka ethatha inxaxheba kolu 
phando. 
 
Ukuba unemibuzo enxulumene nolu phando, iinjongo okanye iinkqubo zalo uvumelekile 
ukuqhagamshelana noGqr. Green okanye uGqr. van Zyl kwiCandelo loNyango lwezifo 
ezinxulumene namathumba kwa-G3 eTygerberg (Tygerberg G3 Oncology Unit) kwa-021 938 
4564. 
Ukuba unemibuzo enxulumene namalungelo omntwana wakho njengomntu osetyenziswa 
kuphando, qhagamshelana noNkskz. Maléne Fouché [mfouche@sun.ac.za; 021 808 4622] 
kwiCandelo loPhuhliso loPhando.  
IMVUME EFANELEKILEYO YABAZALI / YABANTU ABAKHULISA 
UMNTWANA NGOKUSEMTHETHWENI 
(egameni labantwana abangaphantsi kweminyaka eli-15 ubudala) 
Mna ...………………… ngenxa yoko ndiqinisekisa ukuba ndazisiwe ngumphandi,  
uGqr.……..…….……… ngohlobo, indlela oluqhutywa ngayo, iinzuzo nemingcipheko yolu 
phando lwezonyango. Kananjalo ndifumene, ndafunda ze ndaqonda zonke iinkcukacha 
ezibhalwe apha ngasentla (kwiPhetshana leeNkcukacha zeSigulana kunye neMvume 
eFanelekileyo) ezinxulumene nolu phando lwezonyango. Ndiyazi ukuba iziphumo zolu 
phando, kuqukwa iinkcukacha zomntwana wam buqu eziphathelene nomhla wokuzalwa, 
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onobumba bokuqala bamagama akhe neziphumo zokuxilongwa kwakhe ziya kuqwalaselwa 
kungaziwa ukuba zezikabani kwingxelo yophando.  
Ndinakho ukuthi, nanini na, ngaphandle kokugwetywa, ndiyirhoxise imvume yam yokuthatha 
inxaxheba komntwana wam kolu phando. Ndibe nethuba elaneleyo lokubuza imibuzo 
(ngokuzithandela kwam) kunye nokwazisa ukuba umntwana wam ukulungele ukuthatha 
inxaxheba kolu phando.   
 
 
.......................................................                ........................................................... 
Igama lomzali/lomntu okhulisa   Utyikityo lomzali/lomntu okhulisa 
umntwana ngokusemthethweni                      umntwana ngokusemthethweni 
…………………….. 
Umhla............................................... 
.......................................................                ........................................................... 
Igama lesigulana                                              Utyikityo lwesigulana 
……………………. 
Umhla............................................... 
.......................................................               ............................................................. 
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Appendix D Child assent form 
  
 
CHILD ASSENT FORM 
 
I am Dr Green from Stellenbosch University. I am doing a research study to figure 
out why some children with cancer become sicker than others. We are asking you to 
take part in the research study because with the information we collect we might 
be able to help you and other children to get better. It will also help us to better 
understand what happens to you when you become sick. 
For this research, we will use information of your cancer type and treatment, 
current illness and results of blood and other tests. We will keep all your 
information private, and will not show it to anybody not directly involved in the 
research. Only people from Stellenbosch University working on the study will see it. 
Because you are currently sick and have a fever, blood and other tests will be done 
to help you get better. We will not do any other tests. We will only use the 
information (and test results) from your folder in our research. 
With the information we collect from your records, we might be able to better help 
you and other children in the future. Using this information we hope to predict 
which children will become sicker than others, thus making it possible to help them 
sooner. 
You should know that: 
 You do not have to be in this study if you do not want to.  You won’t get 
into any trouble if you say no.  
 You may stop being in the study at any time.  
 Your parent(s)/legal guardian(s) were asked if it is OK for you to be in this 
study.  Even if they say it’s OK, it is still your choice whether or not to take 
part.   
 You can ask any questions you have, now or later.  If you think of a question 
later, you or your parents/legal guardian(s) can contact us. 
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 If you have any questions regarding the research study, its aims or procedures 
you or your parents can contact Dr Green or Dr van Zyl at the Tygerberg G3 
oncology unit at 021 938 4564. 
 If you have questions regarding your rights as a research subject, contact Ms 
Maléne Fouché [mfouche@sun.ac.za; 021 808 4622] at the Division for 
Research Development.  
 
Sign this form only if you: 
 Have understood what you will be doing for this study, 
 Have had all your questions answered, 
 Have talked to your parent(s)/legal guardian(s) about this project, and 




Your Signature             Printed Name              Date 
 
______________________________________ 
Name of Parent(s) or Legal Guardian(s) 
 
______________________________________________________ 




















Appendix E Kinderinstemmingsvorm 
 
Kinderinstemmingsvorm 
Ek is Dr Green van Stellenbosch Universiteit. Ek is besig om ‘n 
navorsingsprojek te doen om uit te vind hoekom sekere kinders met kanker 
sieker word as ander. Ons wil graag hê jy moet deelneem aan ons projek 
sodat ons jou and ander kinders met kanker kan help om beter te word en 
ook sodat ons jou siekte beter kan verstaan.  
Omdat jy nou siek is met ‘n hoë koors gaan die dokters bloed trek en ander 
toetse doen om jou te help om beter te word. Ons wil graag die inligting van 
jou siekte en die uitslae van jou toetse gebruik. Jou inligting sal ‘n geheim bly 
en niemand behalwe die mense betrokke by die projek sal dit sien nie. 
Met die inligting wat ons versamel van jou en ander kinders wat aan ons 
projek deelneem, wil ons kyk of ons kan voorspel watter kinders sieker gaan 
word as ander. Op hierdie manier kan ons kinders met dieselfde siekte help 
om nie sieker te word nie. 
Jy moet weet dat: 
 Dit jou keuse is om aan ons projek deel te neem en indien jy nie sou 
wou deelneem nie, jy nie in die moeilikheid sal kom nie. 
 Jy enige tyd kan kies om nie deel te neem of om te onttrek van ons 
projek. 
 Ons met jou ouers/voog gepraat het en dit OK is met hulle dat jy 
deelneem.  
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 Jy enige vrae kan vra, nou of later. As jy eers later aan iets dink kan jy 
of jou ouers/voog ons kontak.   
 As jy enige vrae oor die navorsing, sy doelwitte of prosedures het, kan 
jy of jou ouers Dr Green of Dr van Zyl by die Tygerberg G3 onkologie-
eenheid by 021 938 4564 kontak.  
 As jy enige vrae het oor jou regte as 'n studiedeelnemer, kontak me 
Maléne Fouché [mfouche@sun.ac.za; 021 808 4622] by die Afdeling 
Navorsingsontwikkeling.  
  
Teken net hierdie vorm: 
 As jy verstaan waaroor die projek gaan. 
 As al jou vrae beantwoord is. 
 As jy met jou ouers/voog gepraat het oor jou deelname aan ons projek.    




Jou handtekening             Naam en Van          Datum 
 
______________________________________ 
Naam van Ouer of Voog 
 
______________________________________________________ 
Navorser se Handtekening             Naam en Van   Datum  
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UXWEBHU LWEMVUME YOMNTWANA 
 
 
NdinguGqr. Green weYunivesithi yase-Stellenbosch. Ndenza uphando ukufumanisa 
ukuba kutheni abanye abantwana abanesifo somhlaza begula kakhulu kunabanye. 
Sicela ukuba uthathe inxaxheba kolu phando kuba ngeenkcukacha esiziqokelelayo 
singanakho ukukunceda wena nabanye abantwana nibe ngcono. Kananjalo kuya 
kusinceda ukuba siqonde ngcono ukuba kwenzeka ntoni kuwe xa ugula. 
 
Ngeenjongo zolu phando, siza kusebenzisa iinkcukacha zohlobo lwesifo sakho 
somhlaza nonyango, isigulo esikhoyo kunye neziphumo zovavanyo lwegazi nezinye 
iimvavanyo. Siza kugcina zonke iinkcukacha zakho ziyimfihlo, kwaye asisayi 
kuzibonisa nabani na ongabandakanyeki ngqo kolu phando. Ngabantu abavela 
kwiYunivesithi yase-Stellenbosch kuphela abasebenza kolu phando abaya kuzibona. 
 
Ngenxa yokuba uyagula ngoku kwaye unefiva uvavanyo lwegazi nezinye iimvavanyo 
ziya kwenziwa ukukunceda ube ngcono. Asisayi kwenza ezinye iimvavanyo nokuba 
zezantoni na. Siza kusebenzisa kuphela iinkcukacha (kunye neziphumo zovavanyo) 
ezikuxwebhu lweenkcukacha zempilo yakho kuphando lwethu. 
 
Ngolwazi esilufumana kwiinkcukacha zakho ezigciniweyo, singakwazi ukukunceda 
ngcono nabanye abantwana kwixesha elizayo. Ngokusebenzisa ezi nkcukacha 
sinethemba lokuthekelela ukuba ngabaphi abantwana abaza kugula kakhulu 
kunabanye, ngalo ndlela kube nzima ukubanceda ngokukhawuleza. 




Kufuneka wazi ukuba: 
 Akunyanzelekanga ukuba uthathe inxaxheba kolu phando xa ungafuni. 
Awusayi kungena ngxakini nangayiphi na indlela ukuba uthi hayi.  
 Uvumelekile ukuyeka ukuthatha inxaxheba kolu phando nangaliphi na ixesha.  
 Abazali bakho/abantu abakukhulisayo ngokusemthethweni babuzwa ukuba 
ingaba KULUNGILE na ukuba ubandakanywe kolu phando. Nokuba bona 
bathe KULUNGILE, kuselilungelo lakho ukuzikhethela ukuba uyafuna 
ukuthatha inxaxheba okanye awufuni kusini na.  
 Uvumelekile ukubuza nayiphi imibuzo onayo, ngoku okanye kamva kolu 
phando. Ukuba uthe wacinga umbuzo kamva, wena okanye abazali 
bakho/abantu abakukhulisayo ngokusemthethweni bavumelekile 
ukuqhagamshelana nathi. 
 Ukuba unayo nayiphi imibuzo ephathelene nolu phando, iinjongo okanye 
iinkqubo zalo wena okanye abazali bakho bangaqhagamshelana noGqr. Green 
okanye uGqr. van Zyl kwicandelo lonyango lwezifo ezinxulumene namathumba 
kwa-G3 eTygerberg (Tygerberg G3 oncology unit) kule nombolo yomnxeba: 021 
938 4564. 
 Ukuba unemibuzo enxulumene namalungelo akho njengomntu ekwenziwa kuye 
uphando, qhagamshelana noNksz. Maléne Fouché [mfouche@sun.ac.za; 
021 808 4622] kwiCandelo loPhuhliso loPhando.  
 
Tyikitya olu xwebhu kuphela ukuba: 
 Uyiqondile into oza kulwenzela yona olu phando, 
 Iphendulekile yonke imibuzo yakho, 
 Uthethile nabazali bakho/nabantu abakukhulisayo ngokusemthethweni 
malunga nolu phando, kwaye 
 Uyavuma ukuthatha inxaxheba kolu phando 
_____________________________________________________________________ 
Utyikityo lwakho  Igama elibhalwe ngoonobumba           Umhla 
 
______________________________________ 
Igama lomzali okanye lomntu okukhathalelayo ngokusemthethweni 
 
_____________________________________________________________________ 
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Appendix G Data collection sheet 
Part 1    
Patient folder number       
Study number       
Date of admission     
Number of days admitted before FN episode     
Patient related parameters    
Age      
Gender Male Female  
Temperature     
Pulse rate     
Respiratory rate     
Blood pressure     
Percutaneous oxygen saturation     
Capillary refill time     
Nutritional status W L   
Clinical focus of infection       
Comorbidities       
        
Disease related parameters    
Presence of a central venous catheter Yes No  
Type of central venous catheter Broviac Port  
Type of malignancy       
Phase of chemotherapy       
Number of days since last chemotherapy <7 days >7days  
Biomarkers     
Haemoglobin    Hb≥90g/dl(5) 
Leucocyte count    L<0.3g/dl(3) 
ANC      
AMC      
Platelet count    Plt<50g/dl(3) 
CRP      
PCT     
Blood culture result Positive Negative  
             Organism       
             Sensitivity       
CXR-radiologically confirmed pneumonia Yes No  
Other cultures    
           Urine Positive Negative  
                      Organism       
                      Sensitivity       
           CSF Positive Negative  
                      Organism       
                      Sensitivity       
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           Other       
Chemotherapy more intensive than ALL 
maintenance  Yes (4) No  
Total Prediction Score >/= 9 < 9  
    
    
Part 2    
Outcome before/at 24hours    
SMC (Serious medical complication) Death   
 ICU admission  
 Life threatening event  
MDI (Microbiologically defined infection) Positive blood culture  
 Positive urine culture  
 Positive CSF culture  
 Positive other culture  
Radiologically defined pneumonia Present Absent  
    
Outcome during admission      
Number of days since presentation at time of 
A/E      
SMC  Death    
  ICU admission  
  Life threatening event  
MDI Positive blood culture  
  
Positive urine 
culture    
  
Positive other 
culture Absent  
Radiologically defined pneumonia Present    
       
       
Outcome at follow up      
Number of days since presentation to at time of 
A/E      
SMC Death    
  ICU admission  
MDI 
Positive blood 
culture    
  
Positive urine 
culture    
  
Positive other 
culture Absent  
Radiologically defined pneumonia Present    
       
No adverse event      
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Appendix H NHLS blood culture protocol 
BLOOD CULTURES - COLLECTION AND TRANSPORT 
We recommend that a minimum of 2 blood cultures from different sites should be submitted in 
order to acquire the optimal volume of blood and to facilitate the interpretation of results. 
Anaerobic blood cultures are not available routinely. This test is not cost effective due to low 
number of requests and high cost. 
1. PROCEDURE 
Site selection. 
The phlebotomist should: 
 Select a different site for each blood sample.  
 Avoid drawing blood through indwelling intravenous or intra-arterial catheters. However if 
  blood cultures have been obtained from intravascular catheters, they should be labelled as 
such and one set of blood cultures should also be obtained by venipuncture at the same time 
in order to help assess positive blood cultures from catheters.    
Site preparation.  
 Vigorously cleanse the venipuncture site with 70% isopropyl or ethyl alcohol and wait till 
  dry.  
 Apply 2% tincture iodine or povidone-iodine in ever increasing circles starting at point where 
  venipuncture is to be made. Note: A contact time of 1.5-2 minutes after swabbing is 
necessary   for optimal disinfection.  
 Do not touch the venipuncture site after preparation and prior to phlebotomy. 
 Disinfecting blood culture bottles.  
 Disinfect the top of the bottle or tube with alcohol and allow top to dry. 
Collection of blood. 
 Using syringe and needle insert the needle into the vein, and withdraw blood. Do not change 
  needles before injecting the blood into the culture bottle due to risk of a needle stick injury.  
 After the blood is inserted into the blood culture system mix well to avoid clotting.  
 Use a new needle if vein is missed initially.  
 Add sufficient volume of blood to attain a 1:10 ratio of blood to medium (the volume of blood 
  required is indicated by the manufacturer on the bottle).  
 After phlebotomy, cleanse the site with 70% alcohol to remove remaining iodine, which can 
  cause irritation in some patients and cover puncture wound appropriately.    
2. SPECIMEN VOLUME   
Note: The volume of blood is critical because the number of organisms in the majority of 
bacteraemia is low, especially if the patient is on antimicrobial therapy. In infants and children, the 
number of microorganisms during bacteraemia is higher than in adults; therefore, less blood is 
required for culture.   Recommended volume per bottle: see label on bottle.   
 Children: Ideally, 3 to 5ml of blood should be added to bottle.  
Neonates: 1-3ml of blood per bottle.  
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   Adults: Ideally 10ml blood per culture bottle (aerobic). 
3. RECOMMENDATION ON NUMBER AND TIMING OF BLOOD CULTURES 
4.  A minimum of 20ml (one set consisting of two aerobic bottles) is recommended in order to get an 
optimal yield from blood cultures. It may be desirable to collect sets over 3 consecutive days 
in patients who have been on antimicrobial therapy. 
5. Fever of unknown origin (occult abscess, typhoid fever, or brucellosis): Obtain two separate 
samples initially. It is recommended that a further 2 samples be obtained during temperature 
spike ideally after 24-36 hours of the initial samples. The increase in positive cultures beyond 
four cultures is very minimal.  
6. Suspected endocarditis – collection of blood cultures do not have to coincide with fever spikes due 













Standard Aerobic Culture Bottles 
(Blue caps) – available in wards 
These bottles are generally used 
in most of the bacteraemia and 
fungaemia cases 
The optimal blood volume  
per bottle for culture is 8-
10ml. 
Paediatric Culture Bottles (Yellow 
caps) – available in wards 
These bottles are aerobic and 
are used for low volume 
specimens; such as in neonates 
The optimal blood volume  
per bottle for culture is 1-3ml 
Resin containing Aerobic Culture 
Bottles  (Grey caps) – obtainable 
from lab 
The resin bottles absorb 
antibiotics and the inhibiting 
components out of the blood; 
enhancing the recovery of 
micro- organisms. 
These bottles are generally used 
in cases of disseminated TB; M. 
avium-intracellulare and 
systemic fungal infections. 
Candida and Cryptococcus will 
grow well in standard aerobic 
The optimal blood volume  
per bottle for culture is  
8-10ml.. . 
The optimal blood volume  
per bottle for culture is 1-
5ml. 
  
Myco/F lytic (Mycobacteria, 
fungi)  (red cap) – obtainable 
from lab 




DURATION OF INCUBATION : 
TBH incubates blood cultures for 5-7 days; using an automated system.  When fastidious organisms 
are suspected as a cause of sepsis or infectious endocarditis, e.g. HACEK organisms (Haemophilus 
aphrophilus/paraphrophilus, Actinobacillus actionmycetemcomitans, Cardiobacterium hominis, 
Eikenella corrodens and Kingella kingae), the laboratory should be notified of this possibility, so that 
the blood culture can be incubated for a longer time (14 days). Suspected Brucella is incubated for 28 
days and suspected TB and fungi are incubated for 42 days, before the culture is regarded as negative. 
QUALITY CONTROL: 
Media 
5. Check expiry dates of each batch of blood culture bottles used.  
6. Uninoculated blood culture bottles should be stored in a cool dark place  
7. Examine bottles for turbidity and/or change of colour before adding any blood.  
8. Discard any bottles showing abnormal characteristics.  
Labelling and transport. 
Please ensure that all blood culture bottles are labelled correctly (not over bar code) and that the 
request form is completed with all the relevant required data. All specimens should be transported to 
the laboratory promptly. Failure to do this may result in the death of fastidious organisms and in 
overgrowth by more hardy bacteria.1 
 
  
                                                          
1 NHLS Tygerberg Microbiology Specimen Sampling Manual, January 2006. 
bottles. 
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Appendix I Febrile neutropenia hospital treatment protocol. 
FEVER: 
 >38,5°C 1x/24hours 
 or >38°C    2x/24hours 
EXAMINATION: Skin (especially Broviac/port site, LP and bone marrow lesions), peri-anal, mouth 
and lungs. 
INFECTION WORK UP: 
i. Blood culture (always): repeat culture if temperature stays high (>38ºC)  
NB if a positive culture is found, another culture must always be repeated 
after the infection has been treated. Remember to tick off MCS & fungal 
culture on the request form. 
ii. FBC and differential count (always) 
iii. CRP(always) 
iv. Urine & stool MCS if indicated 
v. Blood chemistry if indicated 
vi. Urgent CXR if respiratory problems 
vii. Throat swab if clinically indicated 
viii. LP if clinically indicated 
ix. Other imaging as indicated 
x. Virus screening and other appropriate investigations where necessary 
xi. Consider echo in case of prolonged fever 
                      
i. FBC: If ANC (Absolute Neutrophil Count) >500 (0.5x109/l), please do an infection 
work up and consider prescribing an oral  broad spectrum antibiotic if clinically 
indicated.  
ii. Treatment of fever if ANC <500 (0. 5x109/l): 
a. Pip-Taz 50mg/kg/dose 6 hourly  
b. Amikacin 1 week to 10 years: 25mg/kg on day 1, then 18mg/kg daily. >10 years: 
20mg/kg on day 1, then 15mg/kg daily (max dose 1,5g) . 
c. If mucositis present or Staphylococcal infection suspected, also add vancomycin 
10mg/kg/dose 6 hourly 
Note: patients with an indwelling central line and fever should get an infection work-
up and receive IV antibiotics.  
 If no improvement within 24 -  48 hours or if a Staphylococcus infection (Gram positive) is suspected, 
add: 
         Vancomycin 10 mg/kg/dose 6 hourly (max. = 3g/d) 
Monitor blood levels of Amikacin and Vancomycin 
Aminoglicoside levels (Therapeutic) 
               Amikacin       Vancomycin 
          Pre           <10                5 - 10 
          Post      20 - 36              15 – 25 
 
 
Consider change of Piptaz to the following antibiotics if extended spectrum organisms are suspected: 
            Meropenem (20-40 mg/kg/dose 8 hourly) (weight >50 kg: 1 g 8 hourly) 
or Ciprofloxacin 10mg/kg/dose (max 400mg) 8 hourly 
 Please note: 
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i. If patient has an indwelling catheter (Broviac) consider Vancomycin after 24 hours. 
ii. If patient is acutely ill or considered to be infected by a possible hospital acquired organism, 
start with Meropenem. 
 
If patient is still feverish after 5-7 days, add anti-fungus treatment as follows:  
    1.  Fluconazole: - mainly prophylaxis and treatment of GIT candidiasis  
           6 mg/kg/day prophylactic 
           6-12 mg/kg/day for systemic infection 
           3 mg/kg/day for mucositis 
 
     2.   Amphotericin-B – if proof of fungal infection: 
           Dose: Start with test dose of 0,1 mg/kg 
           If well tolerated, continue with 0.6-1 mg/kg/day or alternative days over 
           6-8 hours. (discuss on ward round) 
           Monitor urea, creatinine and electrolytes. 
           Potassium supplementation is almost always necessary 
           Phenergan is sometimes necessary before Amphotericin infusion. 
Possibility of removal of broviac catheter must be discussed with consultant in the following cases: 
 Fungal infection 
 Second positive blood culture after course of antibiotics completed 
 Repeated infections with the same organism 
 Broviac tunnel infection 
b. OTHER DOSAGES      
 Ciprofloxacin:       10-20 mg/kg/dose  12 hourly PO or 10mg/kg/dose   
  (max 400mg) 8 hourly IV 
 Ceftriaxone    25-100 mg/kg/day IV 
 Cefuroxime    30-100 mg/kg/day ÷ 3 IV or <2yr 125 mg 2x/day,   
  >2yr 250 mg 2x/day PO 
 Colistin            40 000U/kg 8 hourly IV (needs MCC approval) 
 Cyclocapron:      15-25 mg/kg/dose 6-8 hourly PO or IV  
 ( tablets = 500 mg) 
 Fluconazole:        3-12 mg/kg/day but 8 mg/kg loading dose for    
  systemic infection 
 Meropenem:        20-40 mg/kg 8hrly (weight > 50Kg :  1 g 8hrly) 
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